

Index

a

- AAA. *See* Abdominal aortic aneurysm (AAA)
- ABC. *See* Aneurysmal bone cyst (ABC)
- Abdomen, anatomy of
- adrenal glands 105–106
 - biliary system 90–92
 - bowel, vascularization of 98–100
 - gallbladder 92–93, 94
 - gastrointestinal system 96–100
 - hepato-biliary system and pancreas 86–93
 - inframesocolic compartment 104
 - ligaments 101
 - limbs and joints 123–128
 - liver 86–90
 - mesentery 101, 102
 - omentum 101, 103
 - pancreas 93–95
 - peritoneal compartments 101, 103
 - peritoneum 101
 - retroperitoneum 106–108
 - spleen 100–101
 - supramesocolic compartment 103–104
 - urinary system 104–105
- Abdominal aortic aneurysm (AAA) 298–301, 304
- Abnormal bronchus 76
- Absorbed photon energy 23
- ACC. *See* Adenoid cystic carcinoma (ACC)
- ACCIPIO® 832
- ACCs. *See* Adrenocortical carcinomas (ACCs)
- Accurate attenuation correction 48
- Acetabulum 123
- Acetazolamide 168
- Achalasia 385
- ACM. *See* Alveolar-capillary membrane (ACM)
- Acoustic impedance 43
- Acquired immune deficiency syndrome (AIDS) 443
- Acquisition system
- CT 31, 32
 - PET 35–36
 - on SPECT-CT 21
- Acute aortic dissection 274, 301
- Acute calculous cholecystitis 469
- Acute cerebral infarction 166–167
- Acute cholecystitis 690–691
- Acute coronary syndromes 257
- Acute pulmonary embolus 680–681
- Acute rejection, renal transplant and 526, 527
- Acute tubular necrosis (ATN) 526–528, 679
- AD. *See* Alzheimer's disease (AD); Aortic dissection (AD)
- ADC. *See* Apparent diffusion coefficient (ADC)
- Adenocarcinoma 407, 408
- Adenoid cystic carcinoma (ACC) 224, 228
- Adenomas 429
- Adenomatous polyposis coli (APC) gene 441
- Adrenal adenomas 498–499
- Adrenal cysts 500
- Adrenal glands 105–106
- ACCs 501
 - adenomas 498–499
 - adrenal incidentaloma 497–498
 - anatomy of 497
 - correlative 498–499
 - cysts 500
 - hemorrhage 499–500
 - lymphomas 502
 - metastases 502, 503
 - myelolipomas 498
 - pheochromocytomas 500–503
- Adrenal hemorrhage 499–500
- Adrenal incidentaloma 497–498
- Adrenal lymphoma 502
- Adrenal metastases 502, 503
- Adrenal myelolipomas 498
- Adrenocortical carcinomas (ACCs) 498, 501
- AEFs. *See* Aortoenteric fistulas (AEFs)
- Affine transformation 32
- AI. *See* Artificial intelligence (AI)
- AIDS. *See* Acquired immune deficiency syndrome (AIDS)
- Alanine-serine-cysteine transporter 2 (ASCT2) 539
- Alar fascia 61, 67
- Alberta Stroke Program Early CT Score (ASPECTS) 166
- ALND. *See* Axillary lymph node dissection (ALND)
- Alveolar-capillary membrane (ACM) 315
- Alzheimer's disease (AD) 143, 164, 165
- amyloid PET imaging 173
 - biomarker 172
 - diagnosis of 171
 - early-onset patients 172, 173
 - late-onset patients 173
 - medial temporal atrophy in 173
 - MRI, SPECT, and PET 172–174
 - parietotemporal cortex in 172–173
 - posterior cingulate gyrus and precuneus 172
 - preclinical 172
- Amide proton transfer (APT) 198
- Amiloyd imaging 143–144
- Amino acid tracers 141, 199–207
- FDOPA PET 202
 - FET PET 201–202, 206, 207
 - FLT PET 203
 - FMISO PET 203–204
 - MET PET 200
- Amiodarone induced thyrotoxicosis (AIT) [Type I, II, and III] 487
- Ammonia-13 259, 265
- Amplitude (A-mode) 45
- Amyloid b (Ab) accumulation 164, 165
- Amyloidosis, cardiac 271–272
- Amyloid PET imaging 173
- Anaerobic glycolysis 2
- Anal cancer 437–439
- Analog SiPM (aSiPM) 39

- Analytical methods 38
- Anaplastic gliomas 208
- Anatomical imaging modalities 30
- Anatomic staging, for breast cancer 365
- Anatomy and variants, on cross-sectional imaging 52
- Anatomy of brain 53
- basal ganglia 57–58
 - cerebral cortex 55–57
- CNS
- anatomy of coverings of 54
 - compartments and structures of 54
- cranial nerves 59–60
- parenchyma 54–55
- posterior fossa 61
- semiology in neuroimaging 53–54
- ventricular system 61
- white matter 58–59
- Aneurysmal bone cyst (ABC) 634
- Anger camera 33
- components of 34
 - principle 21
- Angiodysplasia 688
- Angiomyolipomas 528
- Angiotensin-converting enzyme inhibitors (ACEI) 526
- Angular gyrus 164
- Annihilation coincidence-detection systems 355–356
- Annihilation process 35
- Anterior aortic arch 81
- Anterior fibromuscular stroma (AFMS) 533
- Anterior oral cavity 232
- Anterior pararenal space 106, 107
- Anterior segment bronchi 76, 79
- Anterior subphrenic space 104
- Anterior temporal pole 164
- Antibody-dependent cellular-mediated cytotoxicity (ADCC) 859
- Antineutrophil cytoplasmic antibody (ANCA) 285
- Aorta
- diseases of 274
 - large vessel vasculitis of 288
- Aortic arch and aorto-pulmonary window 81–83
- Aortic dissection (AD) 301–302
- Aortic wall, changes in 286
- Aortitis, imaging of 292
- Aortoenteric fistulas (AEFs) 303–305
- Apical segment bronchus 76, 79
- Apparent diffusion coefficient (ADC) 138, 197, 334, 346, 412
- Appendiceal malignancies 427–432
- appendiceal NET imaging 428–429
 - mucinous neoplasms 429–431
- Appendix adenocarcinoma 431
- Area under the curve (AUC) 333
- Arm, compartments of 126–127
- Arrhythmia 271
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) 271
- Arterial partial pressure of carbon dioxide ($P_a\text{CO}_2$) 168
- Arterial spin labeling (ASL) 196, 197
- Arterial spin labeling MRI (ASL-MRI) 166, 169
- Arthritis
- degenerative 590, 592
 - rheumatoid 585–589
 - ^{18}F -FDG PET/CT 586, 588–589
 - MRI 586
 - $^{99\text{m}}\text{Tc}$ -MDP scan 586, 587
 - radiography 585–586
 - ultrasound 586
 - spondyloarthropathies 589–591
- Artifacts 219–221
- anatomical conditions of 219
 - dental metal 219, 220
 - reciprocal compensation of 222
 - swallowing 220, 223
 - in ultrasound images 44
- Artificial intelligence (AI) 208
- deep learning (DL) 826–830
 - deep learning-based automatic detection (DLAD) 834
 - deep morphology aided diagnosis network (DeepMAD) 833
 - diagnostic imaging 832–835
 - DLAD-assisted doctor 834
 - DL-based algorithm 833
 - hardware 830
 - learning-based approach 835
 - lung nodule detection 832
 - segmentation algorithms 833
 - software 830
- ARVC. *See* Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- ASL. *See* Arterial spin labeling (ASL)
- ASPECTS. *See* Alberta Stroke Program Early CT Score (ASPECTS)
- Aspiration area (RA) 386
- Aspiration percentage (PA) 386
- Atheromas. *See* Atherosclerotic plaques
- Atherosclerosis 286
- imaging of 292–295
 - lesions, FDG uptake 293
- Atherosclerotic plaques 292
- Atlas-based methods 48
- ATN. *See* Acute tubular necrosis (ATN)
- ATN biomarker 172
- Atrophic gastritis 444
- Atropine 258
- Attenuation 34, 43
- Attenuation coefficients 43
- Attenuation correction artifacts 12
- ATTR. *See* Transthyretin amyloidosis (ATTR)
- Autoimmune thyroiditis 700
- Autologous hematopoietic stem cell rescue (AHSCR) 847
- Autosomal dominant disorder 441
- Avalanche photodiodes (APDs) 39
- Axillary lymph node dissection (ALND) 361
- Axillary lymph node metastasis, PET and 366
- Axillary lymph nodes 351, 352
- FDG avidity in 363
- Azygo-esophageal recess 83–84
- Azygos lobe 81
- b**
- Ball-and-socket joint 123
- Bannayan–Ruvalcaba–Riley syndrome 441
- Barium 397–398
- Barium swallow videofluoroscopy
- esophageal transit, radiologic evaluation of 384–385
 - motility disorders investigated with 385
 - patient with esophageal candidiasis 390
 - patient with Zenker's diverticulum 390
- Barrett metaplasia 444
- Basal ganglia (BG), anatomy of 57–58
- Basal trunk 79
- BBB. *See* Blood–brain barrier (BBB)
- Beam hardening artifact, in PET-CT 12, 14
- Behavioral variant of frontotemporal dementia (bvFTD) 175, 176
- Benign breast conditions 363
- Benign gastric diseases
- gastric emptying
 - functional disorders of 390–391
 - radionuclide evaluation of 391
 - ulcers 413
- Benign gastrointestinal (GI) disorders 383
- Benign liver tumors 468, 470, 471
- Benign prostatic hyperplasia (BPH) 534
- Benign tumors 226
- Benzodiazepine receptor imaging 177
- Bile duct obstruction 473, 476
- Biliary atresia 457
- Biliary leaks 475, 477, 691
- Biliary system, anatomy of 90–92
- Bilinear segmentation-scaling method 38
- Biomarker subtypes of breast cancer 351
- Bladder cancer 530–531
- Bland thrombosis 295
- Blood–brain barrier (BBB) 53, 194
- Blood oxygen level-dependent (BOLD) 163
- Blood supply 310
- BOLD. *See* Blood oxygen level-dependent (BOLD)
- Bone anatomy of cranial fossa 54
- Bone metastases in breast cancer 367, 369
- Bone mineral density (BMD) 659. *See also* Osteoporosis

- Bone scan
 - bone and soft-tissue tumors 605
 - multiple myeloma 640
 - spine metastases 642–643, 646
 - Bone scintigraphy 577
 - chronic nonbacterial osteomyelitis 696
 - Legg–Calvé–Perthes disease (LCPD) 696–697
 - neuroblastoma 697–698
 - occult fracture 578
 - periprosthetic infection 598
 - stress fractures 583
 - ^{99m}Tc-labeled disphosphonates 696
 - Bone SPECT/CT (BSCT) imaging, spinal trauma 648–649
 - Bowel, vascularization of 98–100
 - Bowel wall, patterns of 400
 - Boyden classification, bronchopulmonary segmental anatomy and 310
 - Brachiocephalic artery, trunk of 80
 - Brain
 - anatomy of 53
 - basal ganglia 57–58
 - bone anatomy of cranial fossa 54
 - of cerebral cortex 55–57
 - cranial nerves 59–60
 - lobar and cortical anatomy 55
 - parenchyma 54–55
 - posterior fossa 61
 - semiology in neuroimaging 53–54
 - ventricular system 61
 - white matter 58–59
 - CNS
 - anatomy of coverings of 54
 - compartments and structures of 54
 - tumors
 - classification 194
 - epidemiology and symptomatology 194
 - Brain death 683
 - Brain flow imaging
 - in brain death 709
 - cisternography 709
 - ommaya reservoir 709
 - planar radionuclide angiogram 708
 - Brain ischemia 165
 - Brain perfusion, neuronuclear imaging of 163
 - Brain tumors
 - advanced modalities 789
 - advantages 789
 - central nervous system (CNS) 788
 - computed tomography 788
 - ¹⁸F-fluoromisonidazole (FMISO) 789
 - limitations 788
 - radiotracers 789
 - volumetric interpolated breath-hold examination (VIBE) 789
 - Breast, anatomy of 351
 - Breast cancer
 - biomarker subtypes 351
 - histopathological subtypes 351
 - lymphoscintigraphy role in staging 360–361
 - molecular subtypes 351
 - peripheral and nonperipheral 356
 - PET 362–363, 371
 - and axillary lymph node evaluation 366
 - future of 369–370
 - initial staging 365–366
 - suspected disease recurrence and restaging 369
 - radioguided surgery of 158
 - supplemental screening 356–357
 - systemic treatment of 368–369
 - treatment response, evaluation of 367–368
 - Breast imaging
 - alternative to MRI 357
 - BI-RADS 356
 - dedicated molecular breast-imaging systems 354
 - diagnostic 357
 - early scintimammography 354
 - image-guided biopsies 358
 - lymphoscintigraphic 362
 - MBI 354, 355
 - molecular techniques in 352–360
 - nonmolecular imaging modalities 353
 - nuclear medicine 371–373
 - single-photon gamma imaging systems 354–355
 - ultrasound 353
 - Breast-imaging reporting and data system (BI-RADS) 356, 357
 - Breast lymphoscintigraphy
 - imaging 362
 - injection technique 361–362, 363
 - role in cancer 360–361
 - Breast-specific gamma imaging (BSGI) 354, 357
 - Brightness (B-mode) 45
 - Bronchopulmonary segmental anatomy 308
 - and Boyden classification 310
 - fissures 308
 - nomenclature of 308
 - right and left lung 309
 - Bronchus, anatomy of 74–80
 - axial CT image 75
 - left bronchus 79
 - normal bronchial tree 75
 - right bronchus 74–78
 - Brown adipose tissue (BAT) 5, 6, 776
 - BSGI. *See* Breast-specific gamma imaging (BSGI)
 - Buccal space 66
 - Buccal squamous cell carcinoma, recurrent 299
 - Buccopharyngeal fascia 61, 62
 - “Butterfly glioblastoma” 195
 - bvFTD. *See* Behavioral variant of frontotemporal dementia (bvFTD)
- C**
- CABG. *See* Coronary artery bypass surgery (CABG)
 - CAC. *See* Coronary artery calcium (CAC)
 - ¹¹C-acetate PET/CT
 - bladder cancer 531
 - prostate imaging 538–539
 - renal masses 530
 - CAD. *See* Coronary artery disease (CAD)
 - Cadmium zinc telluride (CZT) 23, 39
 - CAD-RADS. *See* Coronary Artery Disease Reporting and Data System (CAD-RADS)
 - CA-125 levels, post-ovarian cancer therapy assessment 569
 - Cancer-associated fibroblasts (CAFs) 814
 - Capsule endoscopy 407
 - Captopril renography, renovascular hypertension 526
 - Carbonic anhydrase IX (CAIX) 530
 - Carcinoid syndrome 427, 838
 - Carcinoma of unknown primary (CUP) 137, 238
 - at lung 239
 - at tongue ground 238
 - Cardiac amyloidosis 271–272
 - Cardiac computed tomography angiography (CCTA) 274
 - diagnosis of aortic dissection 274
 - IHD, diagnosis and prognosis of 266–268
 - left anterior descending coronary artery 267
 - Cardiac death, risk of 263, 264
 - Cardiac iron overload 271
 - Cardiac magnetic resonance (CMR)
 - cardiac sarcoidosis, diagnosis of 272–273
 - edema 270
 - role in IHD 268–269
 - Cardiac sarcoidosis 272–273
 - Cardiopulmonary diseases, pulmonary scintigraphy for 325–327
 - Cardiovascular infections
 - cardiac implantable electronic device infections (CIEDs) 721–723
 - infective endocarditis (IE) 720–721
 - prosthetic vascular graft infections 723–725
 - cause of 723
 - diagnosis 723
 - foreign-body inflammatory reaction 724

- Cardiovascular infections (*cont'd*)
 - infected aortic endovascular stent 724
 - test accuracy 723
 - treatment response 724–725
- Carina, level of 79
- Carney–Statakis syndrome 420
- Carotid Occlusion Surgery Study 169
- Carotid space 64
- Cartesian plane 46
- Catheter angiography, renal artery
 - stenosis 526
- CBF. *See* Cerebral blood flow (CBF)
- CBV. *See* Cerebral blood volume (CBV)
- ¹¹C-choline PET/CT 139
 - prostate imaging 537, 538
- CCTA-derived fractional flow reserve (CT-FFR) 266
- CD. *See* Celiac disease (CD); Crohn's disease (CD)
- CECT. *See* Contrast-enhanced CT (CECT)
- Celiac disease (CD) 441
- Centiloids 173
- Central nervous system (CNS) 194
 - anatomy of coverings of 54
 - compartments and structures of 54
 - imaging 681–685
- Central zone (CZ), prostate gland 533
- Cerebral blood flow (CBF) 165, 169, 196
- Cerebral blood volume (CBV) 165, 166, 196, 197
- Cerebral commissures 59
- Cerebral cortex, functional anatomy
 - of 55–57
- Cerebral hyperperfusion syndrome (CHS) 169–170
- Cerebral metabolic rate of oxygen (CMRO₂) 166, 167
- Cerebral perfusion 681–683
- Cerebral vasoreactivity (CVR) 168
- Cerebrospinal fluid (CSF) 53, 61
- Cerebrovascular disease 165–170
 - hemodynamic risk evaluation in 167–169, 170
 - ischemic severity evaluation in 166–167
 - postoperative CHS 169–170
- Cervical cancer 445
- Cervical lymph node metastasis 250
- Cervical spine 117–119
 - kyphoscoliosis 223
 - lower 118–119
 - sequential interpretation of 119
 - upper 117–118
- Cervix 110
- CEST. *See* Chemical exchange saturation transfer (CEST)
- ¹¹C-Flumazenil 178
- CFR. *See* Coronary flow reserve (CFR)
- Chemical exchange saturation transfer (CEST) 198
- Chemical shift MRI, adrenal
 - adenomas 498
- Chemotherapy 239, 240
- Chest pain 671
- Chest radiography (CRs) 311
 - mediastinal tumors 344–345
 - pleural diseases 343
 - SPN detection 333
 - teratomas 347
 - thymoma 345
- Chest X-ray for lung cancer 335
- Cholangiocarcinoma 468, 469
- Cholecystocolonic fistula 472, 475
- Cholecystojejunostomy 475, 478
- Choledochal cysts 457, 458
- Choline 139–141
- Chordoma, spinal 636–638
- Chronic aortic dissection (AD) 302
- Chronic cerebrovascular disease 167–169
- Chronic gastroesophageal reflux 444
- Chronic obstructive pulmonary disease (COPD) 324–325
- Chronic rejection, renal transplant
 - and 528
- CHS. *See* Cerebral hyperperfusion syndrome (CHS)
- Classical lissencephaly 180
- CMD. *See* Coronary microvascular dysfunction (CMD)
- ¹¹C-methionine PET 181
- CMR. *See* Cardiac magnetic resonance (CMR)
- CNS. *See* Central nervous system (CNS)
- Cobblestone lissencephaly 180
- Coccyx 123
- Cochlear nerve 60
- Collecting system phase, in
 - nephrography 523
- Colon
 - cancer
 - multiple diagnoses of 436
 - recurrent 437
 - FDG uptake 5
 - transverse diameter of 98
- Colonic-type neoplasms 431
- Colon transit scintigraphy 394–395, 396, 397
- Color Doppler ultrasound
 - prostate imaging 535
 - renal transplant evaluation 527
 - testicular torsion 675
- Colorectal cancer 432–437
- Commissural fibers 59
- Common bile duct 97
- Common hepatic artery (CHA) 89
- Complete response (CR) 195
- Computed tomography (CT) 1, 2, 30–31, 49, 133, 219
 - acquisition system 31, 32
- acute cholecystitis 690
- adrenal
 - hemorrhage 499
 - myelolipoma 499
- AEF 304
- angiography 153
- base ganglia, supratentorial axial of 57
- bladder cancer 530
- bone and soft-tissue tumors 605
- cerebral edema 681, 682
- COVID-19 327
- dual-energy 33
- evaluation of GIST 423
- fracture lines 583
- gastric adenocarcinoma 413
- gastrointestinal contrast agent and 10
- GI tract bleeding 687
- hepatic
 - cholangiocarcinoma 468
 - hemangioma 468, 470
 - lymphoma 466
 - metastases 460, 462, 464
- image of pelvic region 8, 9
- intermediate bronchus 77
- intravenous and oral contrast in 7–10
- ionizing radiation 52
- Krukenberg tumors 416
- lower pelvis from cranial 125
- mediastinal tumors 345
- vs. MRI 53
- multislice scanners 52, 53
- nephroureteral obstruction 523
- NETs 513
- nuclear medicine physicians and 4
- oral cavity 66
- osteoporosis 662, 664
- ovarian cancer 565
- paranasal sinuses 71
- physical principle on 31–32
- pituitary imaging 496
- pleural disease 343–344
- post-ovarian cancer therapy
 - assessment 569
- principle of 7, 10
- prostate imaging 535
- protocols in PET-CT 11
- Rathke's cleft cysts 497
- reconstruction methods 32–33
- renal masses 528, 529
- representation of images 32
- right upper lobe bronchus 76
- semiology of brain 53
- small bowel 400–401
- spinal
 - chordoma 637, 638
 - EC 634
 - fibrous dysplasia 634
 - GCTs 634
 - hemangioma 635, 636

- infection 626–627
 - lymphoma 637
 - metastases 642, 645
 - osteoblastoma 632–633
 - osteoid osteoma 631, 632
 - osteosarcoma 637, 639
 - SPN 333
 - teratomas 347
 - thoracic anatomy 73–74
 - thymoma 345
 - thyroid imaging 489
 - upper pelvis from cranial 124
 - Computed tomography angiography (CTA) 526
 - Computerized tomography pulmonary angiography (CTPA) 313
 - Conduction zone 308–310
 - Continuous wave (CW) Doppler 46
 - Contrast-enhanced CT (CECT) 286, 295
 - spinal infection 627
 - Contrast-enhanced magnetic resonance imaging (CE-MRI) 353
 - Contrast-enhanced US (CEUS) 768–769
 - hepatic
 - hemangiomas 468
 - metastases 459–461
 - rheumatoid arthritis 586
 - Conventional angiography 286
 - Conventional gamma camera 23
 - Conventional mammography 353
 - Converse piezoelectric effect 44
 - Convolutional neural networks (CNNs) 826
 - Cornu ammonis 178
 - Coronary artery bypass surgery (CABG) 266
 - Coronary artery calcium (CAC) 266
 - Coronary artery disease (CAD) 261
 - Coronary Artery Disease Reporting and Data System (CAD-RADS) 267
 - Coronary calcium scoring, in ischemic heart disease 266
 - Coronary flow reserve (CFR) 262, 264
 - Coronary microvascular dysfunction (CMD) 262
 - Coronavirus disease 2019 (COVID-19) 327–328
 - Correlation, defined 1
 - Correlative assessment, across nuclear medicine and radiology 212
 - Correlative imaging 1–2
 - Corticobasal degeneration (CBD) 189
 - Corticobasal syndrome (CBS) 175
 - Coulomb interactions 35
 - COVID-19 infection
 - CT imaging 327
 - FDG PET/CT imaging 328
 - nuclear medicine 328
 - SPECT/CT 328
 - symptoms of 328
 - ventilation scintigraphy 327–328
 - Cowden disease 441
 - ¹¹C-PiB PET 165, 174
 - ¹¹C-Pittsburgh Compound-B (PiB) 173
 - CPP. *See* Cerebral perfusion pressure (CPP)
 - CR. *See* Complete response (CR)
 - Cranial nerves
 - anatomy of 60
 - overview of 59–60
 - Craniocaudal (CC) 353
 - Crohn's disease (CD) 396–397, 442–443
 - Cross-sectional imaging
 - anatomy and its variants on 52
 - CT 52
 - CRs. *See* Chest radiography (CRs)
 - CT. *See* Computed tomography (CT)
 - CT angiography, GI tract bleeding 686–688
 - CT pulmonary angiogram (CTPA) 681
 - CUP. *See* Carcinoma of unknown primary (CUP)
 - CVR. *See* Cerebral vasoreactivity (CVR)
 - Cyclosporin nephrotoxicity 527
 - Cystic duct sign 472, 473
 - Cysts, adrenal 500
 - Cytoreductive surgery (CRS) 429
- d**
- dbPET. *See* Dedicated breast positron emission tomography systems (dbPET)
 - DBT. *See* Digital breast tomosynthesis (DBT)
 - DCE-MRI, bone and soft-tissue tumor biopsy 606
 - DCF. *See* Deep cervical fascia (DCF)
 - DECT. *See* Dual-energy CT (DECT)
 - Dedicated breast positron emission tomography systems (dbPET) 353, 355
 - Dedicated molecular breast-imaging systems 354
 - Deep cervical fascia (DCF) 61
 - Deep layer of the deep cervical fascia (DLDCF) 61, 119
 - Deep learning (DL)
 - advantage of 827
 - applications of 827
 - CNNs 826–827
 - discriminative approaches 827–828
 - generative approaches 829–830
 - graphics processor units (GPUs) 826
 - image translation 829–830
 - labeling and annotations 831
 - overfitting 831
 - privacy and ethical issues 831
 - rare conditions and diseases 831
 - representation learning 828–829
 - support vector machines (SVMs) 826
 - Deep learning-based automatic detection (DLAD) 834
 - Deep morphology aided diagnosis network (DeepMAD) 833
 - Default mode network (DMN) 163
 - activation of 164
 - anatomy and function 164
 - Ab accumulation and 164, 165
 - concept 163–164
 - functional hubs 164
 - modulation 165
 - pathophysiology 164–165
 - task-induced deactivation in 163
 - Degenerative arthritis 590, 592
 - Delayed second tumors, in head and neck 250
 - Delayed third tumors, in right piriform sinus 250
 - Dementia 170–177
 - Alzheimer's disease 171–174
 - cause of 171
 - diagnosis of 136, 170–171
 - DLB 174
 - frontotemporal dementia 174–176
 - idiopathic NPH 176, 177
 - Dementia with Lewy bodies (DLB) 174
 - Dental metal artifacts 219, 219
 - effect depends on degree of head reclination 222
 - in MRI 219
 - in PET-CT 220
 - Dental metal impact in MRI techniques 224
 - Dermal injection technique 361, 362
 - Diabetic foot infection 591, 593–595
 - diagnosis 731–732
 - ¹⁸F-FDG PET and PET/CT 594–595
 - MRI 593
 - PET/MRI 594
 - plain radiography 593
 - SPECT/CT 594
 - three-phase ^{99m}Tc-MDP bone scan 593–594
 - WBC scintigraphy 731
 - Diabetic patients, with IHD 266
 - Diagnostic breast imaging 357
 - Diaphragm 86
 - Diaphragmatic apertures 86
 - Diethylenetriamine pentaacetic acid (DTPA) 838
 - Differential cortical retention 523
 - Differentiated thyroid cancer (DTC) 488–492
 - Differentiated thyroid carcinomas (DTC) 698
 - Diffuse esophageal spasm 385
 - Diffuse large B-cell lymphoma (DLBCL) 439
 - Diffuse subtype gastric adenocarcinoma 412, 413

- Diffusion kurtosis imaging (DKI) 197, 198
 - Diffusion tensor imaging (DTI) 58, 198
 - Diffusion weighted imaging (DWI) 166, 219, 334, 346
 - gliomas 197–198
 - ischemic core of 167
 - multiple myeloma 640
 - osteoporosis 666
 - Diffusion-weighted imaging MRI (DW-MRI) 566
 - Digital breast tomosynthesis (DBT) 353
 - Digital SiPM (dSiPM) 39
 - Direct piezoelectric effect 44
 - Disease-based imaging findings
 - cerebrovascular disease 165–170
 - corticobasal degeneration 189
 - dementia. *See* Dementia
 - epilepsy. *See* Epilepsy
 - movement disorder. *See* Movement disorders
 - Display modes, in ultrasound imaging 45
 - Disseminated peritoneal adenomucinosis 430
 - Distant metastases
 - in breast cancer 366–369
 - in lung cancer 340, 433
 - DKI. *See* Diffusion kurtosis imaging (DKI)
 - DLB. *See* Dementia with Lewy bodies (DLB)
 - DLBCL. *See* Diffuse large B-cell lymphoma (DLBCL)
 - DLDCF. *See* Deep layer of the deep cervical fascia (DLDCF)
 - DMN. *See* Default mode network (DMN)
 - DNET. *See* Dysembryoplastic neuroepithelial tumor (DNET)
 - Dobutamine 258
 - Dopamine transporter (DAT) 174
 - Doppler effect, in diagnostic ultrasound 45–46
 - Doppler shift. *See* Doppler effect
 - Dorsal compartment, of forearm 127
 - Dorsal medial subsystems 164
 - Dorsal mPFC 164
 - Double-contrast esophagography 390
 - Double cortex syndrome. *See* Subcortical band heterotopia
 - Double-layer detector technology 33
 - DSCT. *See* Dual-source technology (DSCT)
 - DTC. *See* Differentiated thyroid cancer (DTC)
 - DTI. *See* Diffusion tensor imaging (DTI)
 - Dual blue-dye injection 362
 - Dual-energy absorptiometry, osteoporosis 659–664
 - Dual-energy CT (DECT) 33
 - Dual-energy window (DEW) method 22, 37
 - Dual-source technology (DSCT) 33
 - Duodenal adenocarcinoma 426
 - Duodenum 96–97
 - During-reconstruction approach 37
 - DWI. *See* Diffusion-weighted imaging (DWI)
 - Dynamic contrast-enhanced (DCE) MRI perfusion 196, 197
 - Dynamic (sequential) scintigraphy 522–523
 - renal transplant evaluation 527
 - Dynamic susceptibility contrast-enhanced (DSC) MRI perfusion 196
 - Dysembryoplastic neuroepithelial tumor (DNET) 181, 182
 - Dysplasia 441
- e**
- Early lymph node recurrence 249
 - Early scintimammography, limitations of 354
 - EATL. *See* Enteropathy-associated T-cell lymphoma (EATL)
 - EC. *See* Eosinophilic granuloma (EC)
 - ECE. *See* Extracapsular extension (ECE)
 - ECG. *See* Electrocardiogram (ECG)
 - Echo 43, 45
 - Echocardiography 269, 270
 - Edema 390
 - EEG. *See* Electroencephalography (EEG)
 - EER. *See* Esophageal emptying rate (EER)
 - EGD. *See* Esophagogastroduodenoscopy (EGD)
 - E-GISTS. *See* Extra-gastrointestinal tract tumors (E-GISTS)
 - Elective lymph node dissection (ELND) 764
 - Electrocardiogram (ECG) 257
 - Electroencephalography (EEG) 163
 - Electromagnetic (EM) tracking 48–49
 - Emergency radiology 671–691
 - central nervous system 681–685
 - GI tract bleeding 685–688
 - hepatobiliary imaging 688–691
 - lung scintigraphy 679–682
 - myocardial perfusion imaging 671–674
 - renal scintigraphy 676–679
 - acute tubular necrosis 679
 - urinary tract obstruction 676–679
 - urine leak 679
 - vascular compromise 679
 - testicular torsion 673–676
 - Endocrine diseases, correlative imaging in 485–503
 - adrenal imaging 497–503
 - ACCs 501
 - adenomas 498–499
 - anatomy 497
 - correlative 498–499
 - cysts 500
 - hemorrhage 499–500
 - incidentaloma 497–498
 - lymphomas 502
 - metastases 502, 503
 - myelolipomas 498
 - pheochromocytomas 500–503
 - parathyroid imaging 492–495
 - anatomy and embryology 492
 - 4D-CT 492, 493
 - MRI 493
 - ^{99m}Tc-sestamibi scintigraphy 493
 - overview of 492
 - PET and PET/CT 493
 - SPECT-CT 493–495
 - ultrasound 492
 - pituitary imaging 494–497
 - anatomy 494–496
 - CT 496
 - ¹⁸F-FDG PET/CT 496, 497
 - MRI 496
 - pituitary adenomas 496, 497
 - Rathke's cleft cysts 497
 - thyroid imaging 485–492
 - anatomy 485
 - differentiated thyroid cancer 488–492
 - ¹⁸F-FDG PET/CT 487–491
 - FNA biopsy 485–486
 - function 485
 - hybrid molecular imaging 488–492
 - ¹²³I or ¹³¹I scan 489–491
 - ¹²⁴I-PET/US fusion imaging 489
 - ^{99m}Tc-DMSA scintigraphy 486
 - ^{99m}Tc-MIBI scintigraphy 486, 487
 - nodules 485
 - PET/MRI 492
 - SPECT/CT 489, 491, 492
 - SPECT/US 486
 - thyroid scintigraphy 486
 - ultrasound 485
 - Endoleaks 303
 - Endometrial cancer
 - correlative imaging of 554–555
 - FDG PET/CT 556–561, 563
 - distant metastasis 557, 559
 - lymph node metastasis 557, 558
 - post-therapy assessment 557–561
 - pre-operative local staging 556–557
 - primary diagnosis 556
 - future directions for 563
 - MRI 555–556
 - abnormal findings 556
 - vs. other modalities 556
 - pre-operative local staging 556
 - primary detection 556
 - recurrence 556
 - PET/MRI 561–562
 - PMB and 555
 - pre-operative assessment 555
 - radiation therapy
 - brachytherapy 562

- CT simulation scan 562, 563
 role of imaging in 562
 risk factors for 554
 staging of 555
 TVS 555
 type I 554
 type II 554
- Endometrium, FDG uptake 5
- Endoscopic ultrasound (EUS), in gastric cancer 408, 413
- Endoscopy 407–408
- Endothoracic fascia 85
- Endovascular aneurysm repair (EVAR) 301
- Enteropathy-associated T-cell lymphoma (EATL) 441
- Eosinophilic granuloma (EC) 634
- Epididymitis 676
- Epilepsy 177
 FCD 178–179
 FDG-PET 177
 hemimegalencephaly 179–180
 hippocampal sclerosis 177–178
 miscellaneous 181–183
 neoplasms 181
 other dysplastic diseases 180–181
- Epipharynx. *See* Nasopharynx
- Epiploon. *See* Omentum
- Epithelioid hemangioendothelioma 468, 470
- Epstein–Barr virus (EBV) 227
- Erdheim–Chester diseases 821
- Esophageal candidiasis 389–390
- Esophageal diverticula 389
- Esophageal dysmotility 390
- Esophageal emptying rate (EER) 386
- Esophageal malignancies 408
 with bone metastases 409
 imaging considerations 409–412
 metastatic patterns 409
 with peritoneal carcinomatosis 410
- Esophageal squamous cell carcinoma 408
- Esophageal transit, radiologic evaluation of 384
- Esophageal transit time (ETT) 386
- Esophagogastrroduodenoscopy (EGD) 412, 444
- Esophagus, structural abnormalities of 388–390
- Ethmoid sinuses 71
- EULAR. *See* European League Against Rheumatism (EULAR)
- European League Against Rheumatism (EULAR) 287
- Eustachian tube 62, 64
- EVAR. *See* Endovascular aneurysm repair (EVAR)
- Exercise stress test 257, 258
 contraindications and indications for early termination 259
- Extracapsular extension (ECE) 253–255
 in large lymph node metastasis 254
 in small lymph node metastasis 255
- Extraconal orbital compartment 73
- Extra-gastrointestinal tract tumors (E-GISTS) 420
- Extrahepatic biliary tree 90–92
- f**
- Falciform ligament 101
- Fallopian tube 110–111
 cancer, recurrent 445
- False-negative FDG-avid lesions 363
- False pelvis 109
- False-positive FDG-avid lesions 363
- Familial adenomatous polyposis (FAP) 441
- FAP. *See* Familial adenomatous polyposis (FAP)
- Faraday's law 41, 48
- Fascia 219
- Fast kV-switching technology 33
- FBP. *See* Filtered back projection (FBP)
- ¹⁸F-choline
 molecular structure of 139
 PET/CT 139, 140
- FDG-avid breast lesions 363–364
- FDG PET/CT
 endometrial cancer 556–561, 563
 distant metastasis 557, 559
 lymph node metastasis 557, 558
 post-therapy assessment 557–561
 pre-operative local staging 556–557
 primary diagnosis 556
 neuroendocrine tumors 518
 ovarian cancer 566–568
 post-ovarian cancer therapy assessment 569–571
 prostate imaging 537, 538
- FDG-6-phosphate 3
- FDOPA. *See* Fluoro-dihydroxy-phenylalanine (FDOPA)
- ¹⁸F-DOPA
 and amino acid tracers 141
 molecular structure of 141
 NETs 518–519
 PET-CT, MIP images of 18
- Female pelvis, anatomy of 109
 cervix 110
 ligaments of 112
 ovaries 110–111
 rectum 113–114
 urethra 112
 uterus 109–110
 vagina 111
 vascularization of 112–113
- Female reproductive system, correlative imaging of 554–571. *See also* Endometrial cancer; Ovarian cancer
- FET. *See* Fluoro-ethyl-tyrosine (FET)
- Fever of unknown origin 737–738
- ¹⁸F-FACBC (¹⁸F-fluciclovine) PET/CT 539–541
- ¹⁸F-FDG. *See* Fluorine-18 (¹⁸F)-fluorodeoxyglucose (¹⁸F-FDG)
- ¹⁸F-FDG PET
 adrenal adenomas 499
 adrenal hemorrhages 500
 adrenal metastases 502, 503
 bone and soft-tissue tumors 602, 605, 607
 detection and diagnosis of 602, 605, 606
 prognostic factors 607
 response to therapy 607
 bone metastases 610, 612–614
 diabetic foot infection 594–595
 hepatic
 HCC 467–468
 hemangiomas 468, 471
 metastases 461–463
 hepatic melanomas 466
 hyperparathyroidism and renal osteodystrophy 599, 601
 musculoskeletal imaging
 physiologic uptake 577, 578
 pitfalls 577–581
 osteomyelitis 596
 osteoporosis 666
 periprosthetic infection 597–599
 pheochromocytomas 501
 pituitary
 adenomas 497
 imaging 496
 pituitary imaging 496, 497
 rheumatoid arthritis 586, 588–589
 spinal
 benign lesions 630
 chordoma 637, 638
 cord 647
 EG 634
 hemangiomas 635, 636
 infections 627–628
 malignant lesions 636
 multiple myeloma 640
 osteoblastoma 633
 osteosarcoma 638, 639
 spine metastases 644
 spondyloarthropathies 590, 591
 stress fractures 583
 thyroid
 carcinoma 489–491
 DTC 488
 imaging 487–489
- ¹⁸F-FDG PET/CT
 adrenal adenomas 499
- ¹⁸F-FET 141, 142
- ¹⁸F-florbetaben 143

- ¹⁸F-florbetapir 143
 - ¹⁸F-FLT 141, 142
 - ¹⁸F-fluciclovine 140, 411
 - ¹⁸F-fluoride PET 531
 - ¹⁸F-flutemetamol
 - clinical indications 143
 - molecular structure of 143
 - PET 143, 144
 - FHWM. *See* Full-width at half maximum (FHWM)
 - Fibroblast activation protein (FAP) 814, 862
 - Fibromuscular stenosis 525
 - Fibrous dysplasia 634–635
 - FID. *See* Free induction decay (FID)
 - Filtered back projection (FBP) 32
 - Fine needle aspiration (FNA)
 - biopsy 485–486
 - Fissures 308
 - Fistula formation 445–447
 - Fluid Liquid Attenuation Inversion Recovery (FLAIR) 53, 178
 - Fluorinated PET
 - radiopharmaceuticals 285
 - Fluorine-18 (¹⁸F)-fluorodeoxyglucose (¹⁸F-FDG) 133, 136–139, 199, 286, 401
 - brain glucose metabolism using 164
 - molecular structure of 136
 - PET 264, 265
 - for aortitis 274
 - for cardiac sarcoidosis 273
 - for infective endocarditis 274
 - PET/CT 2, 16, 136–138, 285, 320, 402, 403, 408
 - AAA 301
 - anal cancer 439
 - angiography of heart 153
 - bilateral lung parenchyma 322
 - clinical examples 16–17
 - clinical indications of whole-body 136
 - colon cancer examined by 139
 - COVID-19 328
 - CUP 137
 - esophageal cancer 411
 - gastric cancer 414
 - GISTs 423
 - hibernating myocardium 138
 - image of pelvic region 9
 - lymph node metastases 418
 - lymphomas 440, 443
 - malignant pleural effusion 344
 - massive pulmonary fibrosis 323
 - mechanism of 3
 - in mediastinal tumors 345
 - normal biodistribution 3
 - peritoneal mucinous carcinomatosis 431
 - physiological causes and sites 3, 4, 5–6
 - preparation for 2–3
 - principle of 2–3
 - quantification of 3–4
 - sarcoidosis 320, 321
 - scan acquisition 3
 - in SPN 333–334
 - teratomas 347
 - thymoma 346–347
 - PET/MR 402–404
 - standardized uptake value 199
 - Fluoro-dihydroxy-phenylalanine (FDOPA) 199, 202
 - Fluoro-ethyl-thyrosine (FET) 199, 206, 207
 - Fluoromisonidazole (FMISO), PET 203–204
 - Fluoroscopy images 407
 - Fluoro-thymidin (FLT) 203
 - ¹⁸F-NaF. *See* ¹⁸F-sodium fluoride (¹⁸F-NaF)
 - ¹⁸F-NaF PET/CT
 - benign spinal lesions 630
 - bone metastases 609
 - hyperparathyroidism and renal osteodystrophy 599
 - multiple myeloma 641
 - osteoarthritis 590, 592
 - osteoporosis 599, 666
 - Paget disease 599
 - periprosthetic infection 599
 - prostate cancer 547–548
 - spinal
 - benign lesions 630
 - hemangiomas 635, 636
 - multiple myeloma 640
 - osteosarcoma 638, 639
 - spine metastases 644
 - stress fractures 583
 - traumatic fractures 582
 - Focal cortical dysplasia (FCD) 178–179
 - ILAE classification 179
 - MRI findings of 179
 - 2-year-old boy with 180
 - Foot, compartments of 126
 - Forearm, compartment of 127, 128
 - Fracture risk assessment (FRAX) 659
 - Free induction decay (FID) 41, 42
 - Frequency, of sound waves 42, 43
 - Frontal lobes 55–56
 - Frontal sinus 71
 - Frontoparietal cortices, symmetric atrophy of 189
 - Frontotemporal dementia (FTD) 174–176
 - bvFTD 175, 176
 - progressive nonfluent aphasia 175
 - semantic dementia 175
 - ¹⁸F-sodium fluoride (¹⁸F-NaF) 148, 285
 - bone metastases 134
 - molecular structure 134
 - PET/CT with 134–136
 - uptake 294–295
 - FTD. *See* Frontotemporal dementia (FTD)
 - Full-width at half maximum (FHWM) 36
 - Functional gastric disorders 390–391
 - Functional hubs 164
 - Functional imaging modalities 30
 - Functional motility swallowing disorders 384
 - Fundus 109
- g**
- ⁶⁷Ga-citrate scintigraphy, osteomyelitis 596, 597
 - Gadolinium-based contrast agent (GBCA) 196
 - Gadolinium-enhanced MRA
 - renal artery stenosis 526
 - ⁶⁸Ga-DOTATOC 141–143
 - molecular structure of 142
 - PET/CT, neuroendocrine tumors 142, 143
 - ⁶⁸Ga-Exendin-4 PET/CT 519
 - ⁶⁸Ga-FAPI PET/CT
 - dosimetry results 815
 - future aspects 822
 - imaging protocol 815–816
 - nononcologic application 820–822
 - checkpoint inhibitor-induced 820
 - Erdheim–Chester diseases 821
 - oncologic application
 - advantages 817–818
 - disadvantages 818–819
 - imaging 816–817
 - radionuclide treatment 820
 - target volume delineation 819–820
 - tumor radiotracer uptake 815
 - Gallbladder 92–93, 94
 - Gallium-67 (⁶⁷Ga) citrate 320
 - Gallstone ileus 472, 474
 - Gamma camera 17, 19, 23, 33, 134, 144
 - components of 34
 - PET systems 35
 - Ganglioglioma 181, 182
 - ⁶⁸Ga PET/CT
 - osteomyelitis 596
 - in pulmonary nuclear medicine 320–324
 - ⁶⁸Ga prostate-specific membrane antigen (⁶⁸Ga-PSMA) 140, 204
 - Gas in aortic lumen 304
 - Gastric adenocarcinoma 412–419
 - colonic obstruction caused by recurrent 415
 - CT findings of 413
 - diffuse subtype 412
 - EUS 413
 - imaging in staging 417–418
 - M-staging 418

- N-staging 418
 - T-staging 418
 - Krukenberg tumors relating to 415–416
 - Lauren classification 412
 - metastatic patterns 414–415
 - direct invasion 414
 - hematogenous dissemination 415
 - lymphatic dissemination 414
 - subperitoneal dissemination 414
 - transperitoneal spread 414
 - MRI 413–414
 - PET/CT 414
 - recurrence evaluation 419
 - restaging and monitoring therapy 418–419
 - upper gastrointestinal imaging 412–413
 - WHO classification 412
 - Gastric emptying
 - clinical indications 391
 - functional disorders of 390–391
 - radionuclide evaluation of 391
 - study in patient
 - with diabetic gastroparesis 394
 - with dyspepsia 393
 - with gastroesophageal reflux disease 392
 - Gastric malignancies
 - gastric adenocarcinoma 412–419
 - gastrointestinal stromal tumors 419–424
 - Gastrin-releasing peptide receptor (GRPR) 546
 - Gastrocolic ligament (GCL) 414
 - Gastroesophageal reflux 385, 390
 - Gastrohepatic ligament (GHL) 414
 - Gastrointestinal contrast agent 10
 - Gastrointestinal (GI) lymphoma 407
 - Gastrointestinal scintigraphy
 - gastroesophageal (GE) reflux 709–710
 - gastroparesis 710–711
 - Meckel's diverticulum 711
 - Gastrointestinal stromal tumors (GISTs) 407, 419–424
 - clinical manifestations of 420
 - differential diagnosis 423
 - imaging features 422–423
 - management of patients with 420
 - multicentric small bowel 424
 - neurofibromatosis patient with 421
 - response to therapy in 423–424
 - treatment for 421–422
 - Gastrointestinal system 96–100
 - large intestine 97–98
 - small intestine 96–97, 98
 - spleen 100
 - stomach 96
 - Gastrointestinal (GI) tract 383
 - bleeding 685–688
 - direct invasion from non-GI malignancy 445–447
 - metastatic disease to 444
 - Gaussian distribution 198
 - Gaussian kernel 22
 - GBCA. *See* Gadolinium-based contrast agent (GBCA)
 - GBM. *See* Glioblastoma (GBM)
 - GCA. *See* Giant cell arteritis (GCA)
 - GCT. *See* Giant cell tumor (GCT)
 - Geiger mode 39
 - GE Millenium™ 21
 - Genetic disorders 440–441
 - Geometric center (GC) 394–395
 - calculating method 398
 - GI. *See* Gastrointestinal (GI) tract
 - Giant cell arteritis (GCA)
 - FDG PET/CT study in patient 289
 - US examination in 287
 - Giant cell tumor (GCT) 634
 - GISTs. *See* Gastrointestinal stromal tumors (GISTs)
 - GI tract bleeding. *See* Gastrointestinal (GI) tract bleeding
 - Glioblastoma (GBM) 195, 196
 - resection of right frontal 209
 - Gliomas
 - anaplastic 208
 - arterial spin labeling 197
 - categories 194
 - histomolecular classification 195
 - intra-axial tumor, patient with 210
 - left frontal 202
 - MRI for diagnosis 195–198, 201
 - CEST 198
 - DCE-MRI perfusion 197
 - diffusion-weighted imaging 197–198
 - DSC-MRI perfusion 196–197
 - magnetic resonance spectroscopy 198
 - midline glioma 200
 - nuclear medicine imaging 198–199
 - amino acid tracers 199–207
 - ¹⁸F-fluorodeoxyglucose 199
 - PET/MRI 207–212
 - recurrent IDH-positive, patient with 211
 - response assessment in 195–198
 - WHO grade II and III 195
 - Glomerular filtration rate (GFR) 522, 526
 - Glottic larynx. *See* Glottis
 - Glottis 68
 - Glucose transporters 2, 3
 - Gradients 40
 - Granulomatosis with polyangiitis (GPA) 285, 292
 - Granulomatous inflammations/ infections 320
 - Graves' disease 486
 - Gray matter (GM) 53, 55
 - heterotopia 180–181
 - Greater omentum 101
 - Gross anatomy 308
 - GRPR. *See* gastrin-releasing peptide receptor (GRPR)
 - Gynecomastia
 - in male patients 371, 372
 - in pediatric patients 373
 - Gyromagnetic ratio 40
- ## h
- Half-time excretion ($T_{1/2}$) 523
 - HAMN. *See* High-grade appendiceal mucinous neoplasm (HAMN)
 - HawkEye™ 21
 - Head-neck
 - anatomy 219, 220
 - artifacts, affected by
 - anatomical conditions of 219
 - dental metal artifacts 219
 - swallowing artifacts 220, 223
 - tumors
 - chemotherapy 239–240
 - combined
 - radio-chemotherapy 246–249
 - CUP 238
 - delayed second 250
 - delayed third 250
 - extracapsular extension 253–255
 - nasal cavity and paranasal sinuses 224–225
 - post-therapeutic findings 239–245
 - pre-therapeutic findings 224
 - radiotherapy 243–245
 - surgical procedures 240–242
 - Heart failure 269
 - aorta, diseases of 274
 - left 326
 - with preserved ejection fraction 270–274
 - types of 269–274
 - valvular heart diseases in 274
 - Heart failure with preserved ejection fraction (HFpEF) 270–274
 - ARVC 271
 - cardiac amyloidosis 271–272
 - cardiac sarcoidosis 272–273
 - constrictive pericarditis, diagnosis of 270–271
 - HCM 271
 - Heart failure with reduced ejection fraction (HFrEF) 269–270
 - Heart mediastinum 84–85
 - Helical mode 31, 32
 - Helicobacter pylori* infection 444
 - Hemangiomas
 - hepatic 468, 470, 471
 - spinal 635, 636
 - Hematogenous dissemination, of gastric adenocarcinoma 415
 - Hematoma 527
 - Hemi-liver 87
 - Hemimegalencephaly 179–180, 181

- Hemodynamic parameters 196
 Hemodynamic risk, in cerebrovascular disease 167–169, 170
 Hemorrhage, adrenal gland 499–500
 Hepatic IDA (HIDA) 689
 Hepatic iminodiacetic acid (HIDA)
 scan 456
 acute cholecystitis 471–472
 bile duct obstruction 473, 476
 biliary atresia 457
 choledochal cyst 457, 458
 Hepaticojejunostomy 475, 478
 Hepatic vein, anatomical variants of 93
 Hepatobiliary imaging 456–480
 benign liver tumors 468, 470, 471
 congenital hepatobiliary disorders 457–458
 emergency radiology 688–691
 hepatic metastases
 imaging of 459–464
 origin of 458
 malignant liver tumors 458–468
 neoplasm 458–460
 overview of 456
 primary hepatic malignancy 467–470
 Hepatobiliary scintigraphy 712–713
 Hepato-biliary system 86–95
 Hepatocellular carcinoma (HCC) 467–468, 857
 PET/CT images 300
 Hepatoduodenal ligament (HDL) 414
 Hereditary GI cancer 440–441
 Heterotopic ossification (HO) 584–585
 HGG. *See* High-grade glioma (HGG)
 Hibernating myocardium 138
 HIDA scanning. *See* Hepatic iminodiacetic acid (HIDA) scanning
 High-grade appendiceal mucinous neoplasm (HAMN) 429
 High-grade glioma (HGG) 195
 High probability V/Q scans 311
 High resolution computed tomography (HRCT) 324
 Hilar vessels, anatomy of 74–80
 HIPEC. *See* Hyperthermic intraperitoneal chemotherapy (HIPEC)
 Hippocampal sclerosis 177–178
 clinical characteristics 177
 left 178
 Hippocampus 164
 Histopathological subtypes of breast cancer 351
 HIV. *See* Human immunodeficiency virus (HIV)
 HO. *See* Heterotopic ossification (HO)
 Hounsfield units (HU) 7, 32, 52, 74
 HPV. *See* Human papillomavirus (HPV)
 HRCT. *See* High resolution computed tomography (HRCT)
 HU. *See* Hounsfield units (HU)
 Human immunodeficiency virus (HIV) 443–444
 Human papillomavirus (HPV) 229
 Hybrid imaging 1, 30, 46, 49, 133
 advantages 47
 in diagnosis of PE 312–315
 PET/CT. *See* PET/CT
 PET/MR 47–48
 SPECT-CT. *See* SPECT-CT
 triple modality scanner 48
 Hybrid PET/MRI, detection of prostate cancer 549
 Hydronephrosis 523–524, 676
 Hyperglycemia 394
 Hyperparathyroidism 599, 601
 Hypertension, renovascular 524–526
 Hyperthermic intraperitoneal chemotherapy (HIPEC) 429
 Hyperthyroidism 144, 145
 adverse effects 854
 discharge and follow-up 853
 efficacy 853
 functional imaging 851–852
 pretreatment 853
 safety 853–854
 therapy administration 853
 Hypertrophic cardiomyopathy (HCM) 271
 Hypopharynx 68–69, 219
 recurrence 249
 tumors 236
- i**
- IBD. *See* Inflammatory bowel disease (IBD)
 IBS. *See* Irritable bowel syndrome (IBS)
 ICA. *See* Internal carotid artery (ICA)
 ICD. *See* Implantable cardioverter defibrillator (ICD)
 Idiopathic normal pressure hydrocephalus (INPH) 176, 177
 IHD. *See* Ischemic heart disease (IHD)
 IHPBA. *See* International Hepatic Pancreatic Biliary Association (IHPBA)
¹³¹I human serum albumin 310
¹²³I-Ioflupane 154–155, 156
 ILAE. *See* International League Against Epilepsy (ILAE)
 Ileocolic artery 100
 Ileum 97
 Image degrading factors, in SPECT 34–35
 Image-guided breast biopsies 358
 comparison of 360
 MBI-guided biopsy 359
¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) 156
 NETs 519
 pheochromocytomas 501, 502
¹³¹I-MIBG 519
¹²³I-MIBG. *See*
¹²³I-metaiodobenzylguanidine
 IMLN. *See* Internal mammary lymph nodes (IMLN)
 Immature teratoma 347
 Immunotherapy 246–249, 320
 Immunotherapy-RANO (iRANO) 196
 Implantable cardioverter defibrillator (ICD) 270
 Indeterminate probability V/Q scans 311, 313
 Indium-111 (¹¹¹In)-labeled WBCs 292, 302, 303, 475, 477, 627
 Infection/inflammation imaging
 cardiovascular infections
 cardiac implantable electronic device infections (CIEDs) 721–723
 infective endocarditis (IE) 720–721
 prosthetic vascular graft infections 723–725
 fever of unknown origin 737–738
 future aspects 738
 intraabdominal infections 736–737
 musculoskeletal infections
 acute osteomyelitis 725
 diabetic foot infections 730–732
 left tibial fracture nonunion 726
 periprosthetic joint infections 726–728
 septic arthritis 732
 spondylodiscitis 728–730
 pacemaker pocket infection 722, 723
 pulmonary infections
 pneumonia 732
 sarcoidosis 734–736
 tuberculosis 732–734
 radiopharmaceuticals
 ¹⁸F-fluorodeoxyglucose 720
 ⁶⁷Ga Citrate 717–718
 indium-111 labeled leukocyte scan 719
 invitro labeled leukocyte scintigraphy 718–719
 ^{99m}Tc Diphosphonates 717
 technetium-99m labeled leukocyte scan 719
 Infective endocarditis 274
 Inferior mesenteric artery 100
 Inferior orbital fissure 71–72
 Inferior vena cava (IVC), tumor thrombus in 295
 Infero-anterior nerve 60
 Inflammation 390
 Inflammatory and infectious disorders 441
 Inflammatory arthritis 585–591
 rheumatoid arthritis 585–589
 ¹⁸F-FDG PET/CT 586, 588–589
 MRI 586
 ^{99m}Tc-MDP scan 586, 587

- radiography 585–586
 - ultrasound 586
 - seronegative spondyloarthropathies 589–591
 - Inflammatory bowel disease (IBD) 383, 396–397, 442
 - Infra-hyoid neck 61, 63. *See also*
 - Supra-hyoid neck
 - posterior cervical space 67
 - visceral space 67–69
 - Infrathyoid spaces 220
 - Infrasound 43
 - Innermost intercostal muscle 85, 86
 - Innervation 310
 - ¹³¹I-norcholesterol scans 498
 - ¹¹¹In-oxine-WBC 401
 - Insufficiency fractures 582
 - Interfascial plane 108
 - Intermediate bronchus 76
 - axial CT image 77
 - level of 79
 - Internal carotid artery (ICA) 168
 - Internal mammary lymph nodes (IMLN) 361, 362
 - International Hepatic Pancreatic Biliary Association (IHPBA) 88
 - International League Against Epilepsy (ILAE) 179
 - International Myeloma Working Group (IMWG) 639, 798
 - Interventricular septum 85
 - Intraconal orbital compartment 73
 - Intra-dermal injection 361
 - Intrahepatic biliary tree 90
 - Intravenous contrast, in CT scanning 7–10
 - Intravenous pyelography (IVP) 524
 - Intravenous urography (IVU).
 - See* Intravenous pyelography (IVP)
 - Intravoxel incoherent motion (IVIM) 197
 - Invasive lobular carcinoma 363
 - Investing layer/fascia 61
 - ¹¹¹In-WBC scan 594, 595
 - ¹³¹Iodine 144–145
 - Iodine-123 meta-iodobenzylguanidine (¹²³I-MIBG) 258
 - ¹²⁴I-PET/US fusion imaging 489
 - Irritable bowel syndrome (IBS) 383
 - with diarrhea 392
 - MRI findings in 399
 - Ischemic heart disease (IHD) 257
 - diagnosis and prognosis
 - CCTA 266–268
 - CMR imaging 268–269
 - coronary calcium scoring in 266
 - nuclear cardiology role in 257, 261–266
 - pharmacological stress test 258
 - Ischemic penumbra 166
 - Isocitrate dehydrogenase (IDH) 195
 - Iterative (IR) method 32–33, 38
 - Iterative reconstruction algorithm 22
 - IVIM. *See* Intravoxel incoherent motion (IVIM)
- j**
- Jejunal arteries 100
 - Jejunum 97
 - Joints, anatomy of 123
 - Juvenile polyposis syndrome 441
- k**
- Kaposi sarcoma (KS) 443
 - Kernels 32
 - Kidneys 104–105
 - anatomical variants 104–105
 - renal arteries 105
 - renal veins 105
 - Killian–Jamieson diverticulum 389
 - Krukenberg tumors 415–416
- l**
- Labeled leukocyte imaging,
 - osteomyelitis 596
 - Labeled leukocyte scan 154, 155
 - Lactating breasts, FDG uptake 5
 - Lactation 363, 364
 - LAD. *See* Left anterior descending coronary artery (LAD)
 - LAMN. *See* Low-grade appendiceal mucinous neoplasm (LAMN)
 - Large intestine 97–98
 - Large lymph node metastasis 254
 - Large vessel vasculitides (LVV) 287–291
 - of aorta 288
 - PET/CT 287–289
 - PET/MRI 289
 - scoring methodology 289
 - US 287
 - Larmor equation 40, 41
 - Laryngeal cancer 234, 235, 255
 - Larynx 67–68, 219, 234–235
 - glottis 68
 - subglottis 68
 - supraglottis 67–68
 - tumor recurrence of 245
 - Lateral temporal cortex 164
 - Lauren classification, of gastric adenocarcinoma 412
 - LDCT. *See* Low dose-computed tomography (LDCT)
 - Left anterior descending coronary artery (LAD) 267
 - Left anterior perihepatic space 103
 - Left bronchus, anatomy of 79
 - left lower lobe bronchus 79
 - left upper lobe bronchus 79
 - lingular bronchus 79
 - Left common carotid artery 81
 - Left heart failure 326
 - Left hepatic vein (LHV) 88, 93
 - Left hilum, vascular anatomy of 79–80
 - Left intrahepatic bile duct, anatomical
 - variants of 94
 - Left lower lobe (LLL) bronchus 79, 80
 - Left portal vein (LPV) 88, 89
 - Left posterior perihepatic space 104
 - Left posterior subhepatic space 104
 - Left subclavian artery 81
 - Left supramesocolic space 103–104
 - Left upper lobe (LUL) bronchus 74, 79–80
 - Left ventricular ejection fraction (LVEF) 262, 263, 269
 - Left vertical plane 88
 - Legg–Calvé–Perthes disease (LCPD) 696–697
 - Leptomeninges 54
 - LES. *See* Lower esophageal sphincter (LES)
 - Lesser omentum 101
 - LGG. *See* Low-grade glioma (LGG)
 - Ligaments 101
 - Limbs, anatomy of 123
 - pelvic girdle and lower limbs 123–126
 - shoulder girdle and upper limbs 126–127
 - Linear attenuation coefficient (LAC) 31, 38, 48
 - Line of response (LOR) 35–36
 - Lingular bronchus 79, 80
 - Liver, anatomy of 86–90
 - classical 86
 - Couinaud classification 89, 90
 - fissures 86, 88
 - functional 87–90
 - ligaments 87
 - vascularization of 89
 - Liver Imaging Reporting and Data System (LI-RADS) 467
 - Lymphoma,
 - MIP image of FDG PET-CT 13
 - Locoregional lymph nodes, anatomy
 - of 351
 - Longitudinal magnetization recovery 42
 - Longitudinal relaxation 42
 - Low dose-computed tomography (LDCT) 335
 - Low-dose protocols 22
 - Lower cervical spine 118–119
 - Lower esophageal sphincter (LES) 383, 386
 - Lower leg, compartments of 124, 126
 - Lower limbs 123–126
 - Low-grade appendiceal mucinous neoplasm (LAMN) 429
 - Low-grade glioma (LGG) 195, 196
 - Low probability V/Q scans 311
 - ¹⁷⁷Lu-DOTATATE 142, 839
 - Lumbar spine 121–122

- Luminal blood 286
 - Lung cancer
 - causal risk factor 335
 - clinical symptoms and signs of 334–335
 - initial diagnosis and staging of
 - M staging 336, 340
 - N staging 336–339
 - T staging 335–336
 - residual disease and recurrence 342
 - small cell lung cancer 335, 342, 343
 - treatment 340–342
 - Lung function, presurgical evaluation
 - of 318–319
 - Lung perfusion imaging
 - bronchopulmonary sequestration 705
 - cardiac shunts 704
 - congenital heart disease 704
 - ^{99m}Tc-macroaggregated albumin (MAA) 703
 - neonatal patients 704
 - postsurgical evaluation 705–706
 - pulmonary embolism 706
 - vascular abnormalities 704
 - Lung perfusion scintigraphy 156, 157
 - Lung scintigraphy 679–682
 - Lung transplant rejection 682
 - ¹⁷⁷Lu-PSMA RLT
 - adverse effects 845
 - efficacy 845
 - pre-treatment 844
 - radionuclide therapy 844
 - safety 845
 - therapy administration 844
 - Lutetium-yttrium oxyorthosilicate (LYSO)
 - detector technology 21
 - LVEF. *See* Left ventricular ejection fraction (LVEF)
 - LVV. *See* Large vessel vasculitides (LVV)
 - Lymphatic dissemination, of gastric adenocarcinoma 414
 - Lymphatic drainage 310
 - patterns 432
 - Lymphatic system
 - contrast-enhanced ultrasound scan (CEUS) 768–769
 - ICG lymphography 762
 - intradermal lymphoscintigraphy 749
 - lymphatic imaging 751–752
 - lymphedema 747–748
 - lymphography 748
 - magnetic resonance imaging 769
 - non-invasive 3.0 T MR
 - lymphangiography 769
 - pattern visualization 752–762
 - peristaltic movement of 747
 - PET/CT lymphoscintigraphy 768
 - rest/ stress intradermal
 - lymphoscintigraphy 749, 750, 752, 758
 - sentinel node 763
 - in breast cancer 766
 - in colorectal cancer 768
 - in head and neck cancer 766–767
 - in melanoma 764–765
 - in vulvar cancer 767–768
 - subcutaneous
 - lymphoscintigraphy 748–749
 - superparamagnetic iron oxide (SPIO) nanoparticles 768
 - ultrahigh frequency ultrasound (UHFUS) 762–763
 - Lymph node metastases 249, 250
 - low conspicuity, unusual localization 252
 - recurrence with 253
 - remission
 - after radio-immunotherapy 248
 - of oropharyngeal SCC 246
 - Lymph nodes of neck 69–70
 - anatomical landmarks 69
 - levels 69–70
 - Lymphocele 527
 - Lymphoepithelial carcinoma 227
 - Lymphoma 439–440
 - brentuximab vedotin 773
 - contrast-enhanced CT (CECT) 774
 - Deauville score 775, 776
 - diffusion-weighted imaging (DWI) MRI 779
 - hepatic 466
 - Hodgkin lymphoma (HL) 772, 775
 - MALT 440
 - molecular imaging 773–774
 - non-Hodgkin lymphoma (NHL) 772
 - PET/MRI 779
 - pitfalls
 - false-negative 779
 - false-positive 776, 778–779
 - primary 439
 - programmed
 - cell death-ligand 1 (PD-L1) 773
 - response assessment
 - end-of-treatment response 775–776
 - immunotherapy response 776
 - interim response 774–775
 - staging 774
 - synopsis 779
 - TNM staging system 772
 - treatment in 773
 - WB-MRI techniques
 - aggressive lymphomas 780
 - apparent diffusion coefficient (ADC) 780
 - hodgkin lymphoma 780, 781
 - indolent lymphomas 780
 - synopsis 781
 - Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) 776
 - Lymphomas
 - adrenal 502
 - spinal 636, 637
 - Lymphoscintigraphy in breast cancer 363
 - injection techniques
 - dermal injection technique 361, 362
 - dual blue-dye and radiotracer SLN localization 362
 - peritumoral injections 361, 362
 - role of 360–361
 - Lynch syndrome 441
- m**
- Macro aggregated albumin (MAA) 310
 - Macrophage-laden atheromas 292
 - Macroscopic magnetization (MM) 41
 - Macroscopic magnetization longitudinal (MML) 41
 - Magnet, function of 40
 - Magnetic resonance
 - cholangiopancreatography (MRCP) 690
 - Magnetic resonance imaging (MRI) 1, 2, 40, 49, 133, 163, 219
 - ACCs 501
 - acute cholecystitis 690
 - adrenal myelolipoma 499
 - basal ganglia, anatomy of 58
 - bladder cancer 530
 - components 40
 - CT vs. 52
 - dental metal artifacts in 219, 224
 - diabetic foot infection 593
 - endometrial cancer 555–556
 - abnormal findings 556
 - MRI vs. other modalities 556
 - pre-operative local staging 556
 - primary detection 556
 - recurrence 556
 - evaluation of GIST 423
 - free induction decay and spatial encoding 41
 - gastric adenocarcinoma 413–414
 - gliomas, diagnosis of 195–198
 - hepatic
 - cholangiocarcinoma 468
 - hemangioma 468, 470
 - lymphoma 466
 - metastases 460–462, 464
 - impact of dental metal 224
 - leg, compartments of 126
 - longitudinal magnetization recovery 42
 - malignant pleural disease 344
 - mediastinal tumors 345
 - musculoskeletal sarcomas
 - grading 605
 - staging 601
 - nephroureteral obstruction 524
 - NETs 513

- oral cavity 66
- osteoarthritis 590
- osteoporosis 666–669
- ovarian cancer 565–566
- parathyroid imaging 493
- periprosthetic infection 597
- physical principles of 40
- pituitary imaging 496
- post-ovarian cancer therapy
 - assessment 569
- prostate imaging 535–537
- radiofrequency pulses 52
- Rathke's cleft cysts 497
- renal masses 528, 529
- semiology of brain 53
- seronegative spondyloarthropathies 589
- signal formation 40–41
- small bowel 399–400
 - dynamic phase 399
 - extraintestinal disease 400
 - morphological phase 399
- spinal
 - ABCs 634
 - chordoma 637, 638
 - cord 646–647
 - EG 634
 - GCTs 634
 - hemangioma 635, 636
 - infection 627, 628
 - lymphoma 636, 637
 - osteoid osteoma 631, 632
 - trauma 648
- spine
 - metastases 643–646
 - osteosarcoma 637, 639
- SPN 334
- stress fractures 583
- teratomas 347
- thigh, compartments of 125
- thoracic anatomy 74
- thymoma 346
- thyroid imaging 489
- transverse magnetization decay 42
- urinary tract obstruction 677
- Magnetic resonance spectroscopy (MRS) 198
- Magnetoencephalography 163
- Main pancreatic duct 97
- Main photo-peak energy window 22
- Male patients, gynecomastia in 371, 372
- Male pelvis, anatomy of 114–115
- Malignant change, imaging patterns of 250
- Malignant transformation of glial tumors 198
- Malignant vascular thrombosis, imaging of 295–298
- MALT. *See* Mucosa associated lymphoid tissue (MALT)
- Mandibula 232, 233, 242
- Mantle cell lymphoma 440
- Masticator space 65–66
- Mature teratoma 347
- Maxillary sinus 71
- Maximum intensity projection (MIP) image, of PET-CT 7, 8, 10, 289
- Maximum likelihood expectation maximization (MLEM) 38
- MBI. *See* Molecular breast imaging (MBI)
- MCA. *See* Middle cerebral artery (MCA)
- Mean transit time (MTT) 196
- Mechanical position encoding 49
- Medial prefrontal cortex (mPFC) 164
- Medial temporal atrophy, in AD 173
- Medial temporal subsystems 164
- Mediastinal tumors 344–345
- Mediastinum 80
 - aortic arch and aorto-pulmonary window 81–83
 - heart and paracardiac 84–85
 - normal cardiac anatomy 84
 - pulmonary arteries 83–84
 - supra-aortic 80–81, 82
- Mediolateral oblique (MLO) 353
- Medium vessel vasculitides (MVV) 285, 291–292
- Melanoma, hepatic 466
- Mesentery 101, 102
- Mesorectal fascia (MRF) 113
- MET. *See* Metabolic equivalent (MET); Methionine (MET)
- Metabolic bone disease 599–603
 - hyperparathyroidism and renal osteodystrophy 599, 601
 - osteoporosis 599, 600
 - Paget disease 599, 602
- Metabolic equivalent (MET) 258
- Metabolic penumbra 167, 168
- Meta-Iodobenzylguanidine (mIBG) 156
 - adverse effects 849
 - discharge and follow-up 848
 - efficacy 848
 - functional imaging 846
 - ¹²³I-mIBG 846
 - ¹³¹I-mIBG 846
 - indications of 846
 - laboratory investigations 847
 - oncologic indications 846
 - pretreatment 846–847
 - safety 848
 - therapy administration 847–848
- Metastases
 - adrenal 502, 503
 - spine 641–644
 - bone scan 642–643, 646
 - combined imaging modalities 644–646
 - CT 642, 645
 - CT myelography 642
 - diagnosis of 642
 - ¹⁸F-FDG PET 644
 - ¹⁸F-NAF PET 644
 - MRI 643–646
 - SPECT 643
 - SPECT/CT 643
 - X-ray 642
- Metastasis-directed therapy (MDT) 534
- Metastatic breast cancer, systemic treatment of 368–369
- Metastatic carcinoma rectum, FDG PET-CTs of 17
- Metastatic disease, to GI tract 444
- Methionine (MET) 199, 200
- MIBG. *See* Metaiodobenzylguanidine (MIBG)
- Middle cerebral artery (MCA) 168
- Middle colic artery 100
- Middle hepatic vein (MHV) 87, 93
- Middle layer 61
- Middle lobe (ML) bronchus 76
 - axial CT image 78
 - level of 79
- Middle vertical plane 87
- Mild cognitive impairment (MCI) 143
- MIP. *See* Maximum intensity projection (MIP)
- Miscellaneous 181–183
- MLO. *See* Mediolateral oblique (MLO)
- ⁹⁹Mo 145
- Moderate probability V/Q scans 311
- Molecular breast imaging (MBI) 354, 355, 358–360
 - clinical indications and practical uses of 356
 - image-guided biopsies techniques 358, 359
- Molecular imaging techniques 183
- Molecular prostate imaging 537–545
 - ¹¹C-acetate PET/CT 538–539
 - ¹¹C-choline PET/CT 537, 538
 - FDG PET/CT 537, 538
 - ¹⁸F-FACBC PET/CT 539–541
 - other radiotracers 545–546
- Molecular subtypes of breast cancer 351
- Molecular techniques, in breast imaging 352–360
- Monte Carlo estimations 37
- Motility disorders, investigated with barium swallow videofluoroscopy 385
- Motion (M-mode) 45
- Motion artifacts, in PET-CT 12
- Mouth floor, recurrent tumor after reconstruction 242
- Movement disorders 183
 - corticobasal degeneration 189
 - multiple system atrophy 185–188
 - Parkinson disease 183, 184–185
 - progressive supranuclear palsy 188–189

- mPFC. *See* Medial prefrontal cortex (mPFC)
- MRA. *See* MRI angiography (MRA)
- MR-based attenuation correction (MRAC)
algorithms 48
- MRI. *See* Magnetic resonance imaging (MRI)
- MRI angiography (MRA) 287
- MRS. *See* Magnetic resonance spectroscopy (MRS)
- MSA. *See* Multiple system atrophy (MSA)
- M staging in lung cancer 336, 340
- ^{99m}Tc-diethylenetriamine penta-acetic acid (^{99m}Tc-DTPA) 522
- ^{99m}Tc-dimercaptosuccinic acid (^{99m}Tc-DMSA) 522
- ^{99m}Tc-glucoheptonate 522
- ^{99m}Tc-labeled cholescintigraphy
scintigraphy 689–690
- ^{99m}Tc-MDP bone scan
osteoblastoma 633
osteoporosis 599, 600
rheumatoid arthritis 586, 587
- ^{99m}Tc-MDP SPECT
osteoporosis 599
Paget disease 599
- ^{99m}Tc-mercaptoacetyltriglycine (^{99m}Tc-MAG3) 522
- ^{99m}Tc-methylene diphosphonates (^{99m}Tc-MDP) scan 609–611
- Mucinous (colloid) adenocarcinoma 412
- Mucinous neoplasms 427, 429–431
mucocoele 429–430
pseudomyxoma peritonei 430–431
types 429
- Mucocoele 429–430
- Mucosa associated lymphoid tissue (MALT) 439
- Multidetector computed tomography (MDCT) 313, 335
- Multiparametric prostate MRI (mpMRI) 535–536
- Multiphase bone scintigraphy
HO 585
stress fracture 583
- Multiphase CT (4D-CT) 492, 493
- Multiple imaging protocols 258
- Multiple myeloma (MM) 638–641, 781–784
bone scan 640
combined diagnostic modalities 641
CT 640
DWI 640
MRI 640
PET/CT 640–641
PET/MRI 641
skeletal survey 639
WBCT 640
- Multiple system atrophy (MSA) 156, 185–188
- Multislice CT scanners 52, 53
- Musculoskeletal imaging 577–614
bone scintigraphy 577
degenerative arthritis 590, 592
¹⁸F-FDG PET
physiologic uptake 577, 578
pitfalls 577–581
infection 591, 593–599
diabetic foot 591, 593–595
osteomyelitis 596–598
periprosthetic and other hardware
infection 596–599
spondylodiscitis 596
inflammatory arthritis 585–591
metabolic bone disease 599–603
hyperparathyroidism and renal
osteodystrophy 599, 601
osteoporosis 599, 600
Paget disease 599, 602
metastatic disease 608–614
¹⁸F-FDG PET 610, 612–614
¹⁸F-NaF PET 609
¹⁸F-NaF PET/CT 609
^{99m}Tc-methylene diphosphonates 609–611
normal variations 577–579
primary bone and soft-tissue
tumors 599, 601–608
biopsy 605–606
grading 605
initial detection/diagnosis and
staging 601–605
other PET agents 607, 608
prognostic factors 607
response to therapy 607
restaging and detection of
recurrence 607, 608
relevant anatomy 577
rheumatoid arthritis 585–589
¹⁸F-FDG PET/CT 586, 588–589
MRI 586
^{99m}Tc-MDP scan 586, 587
radiography 585–586
ultrasound 586
seronegative spondyloarthropathies 589–591
stress injuries 582–584
traumatic fractures 579–582
- Musculoskeletal infections
acute osteomyelitis 725
diabetic foot infections 730–732
left tibial fracture nonunion 726
periprosthetic joint infections 726–728
diagnosis 726
⁶⁷Ga imaging 727
molecular imaging 726
shoulder joint replacement surgery 728
symptoms of 726
treatment of 726
- septic arthritis 732
spondylodiscitis 728–730
bone scintigraphy 729
diagnosis 729
infected spinal hardware 729
postoperative 729
postoperative changes 730
symptoms 728
- MVV. *See* Medium vessel vasculitides (MVV)
- Myelodysplastic syndrome (MDS) 843
- Myocardial delayed enhancement (MDE) 268
- Myocardial perfusion imaging (MPI)
151–154, 257, 671–674
prognostic variables in cardiac 263
radiotracers and protocols 258
- Myocardium, FDG uptake 5
- n**
- N-acetylaspartate 198
- Na¹⁸F bone imaging 371
- NaI (TI) scintillation crystals 21, 23
- Nasal cavity
boundaries 70–71
malignant disease of 224–225
and paranasal sinuses 224–225
- Nasopharyngeal carcinoma (NPC) 227, 228
- Nasopharynx 62–64, 219, 227
- National Comprehensive Cancer Network (NCCN) guidelines 547
- Neck. *See also* Head-neck
fascia 61
infra-hyoid. *See* Infra-hyoid neck
lymph nodes of 69–70
supra-hyoid. *See* Supra-hyoid neck
- NECR. *See* Noise equivalent count rate (NECR)
- Negative predictive value (NPV) 262
- Neoadjuvant chemotherapy (NAC) 368
- Neoadjuvant therapy, for breast
cancer 367–368
- Neoplasms 181
- Nephrography, phases of 523
- Nephroureteral obstruction 523–525
- Nephro-urinary tract pathologies 521–531
anatomy 521–522
GFR 522
image acquisition 522–523
dynamic (sequential)
scintigraphy 522–523
static scintigraphy 524
- nuclear medicine
bladder cancer 530–531
nephroureteral obstruction 524, 525
renal masses 528, 530
renal transplant evaluation 527–528
renovascular hypertension 526

- radiology
 - bladder cancer 530
 - nephroureteral obstruction 523–524
 - renal masses 528, 529
 - renal transplant evaluation 527
 - renovascular hypertension 526
 - tubular binding 522
 - tubular secretion 522
 - NETs. *See* Neuroendocrine tumors (NETs)
 - NETTER-1 trial 839
 - Neuroendocrine neoplasms (NEN)
 - checklist 839
 - discharge and follow-up 841–842
 - efficacy 842
 - functional imaging 839–840
 - goals of 840
 - indications of 840
 - overview of 838–839
 - pretreatment 841
 - safety 842–843
 - therapy administration 841
 - Neuroendocrine tumors (NETs) 407, 425–427, 462–465, 512–519
 - appendiceal 428–429
 - CT 513
 - functional imaging
 - FDG PET 518
 - ¹⁸F-DOPA PET 518–519
 - future perspectives 519
 - ⁶⁸Ga-Exendin-4 PET/CT 519
 - ¹²³I-MIBG and ¹³¹I-MIBG 519
 - indications for 515, 516
 - positron emission tomography 513
 - radiopharmaceuticals for 514, 515, 517
 - single-photon emission computerized tomography 513
 - SSTR PET 516, 518
 - targets for 514, 515
 - functional NET 512
 - gastroenteropancreatic 512
 - grading systems 512
 - indications for radiological imaging 512
 - MIP image of 18
 - MRI 513
 - nonfunctional NET 512
 - PET/CT with ⁶⁸Ga-DOTATOC 142, 143
 - transabdominal USG 513
 - tumor heterogeneity 516
 - Neurogenic dysphagia 387
 - Neuroimaging
 - ¹⁸F-sodium fluoride PET 694–695
 - modalities 171
 - PET-CT 693–694
 - PET-MRI 693
 - semiology of brain in 53–54
 - Neuromelanin-sensitive MRI (NmMRI) 184, 185
 - Neuronuclear imaging of brain perfusion 163
 - Neuro-oncology, technological insights and use 207–212
 - NmMRI. *See* Neuromelanin-sensitive MRI (NmMRI)
 - Noise 34
 - Noise equivalent count rate (NECR) 36
 - Nomenclature of bronchopulmonary segmental 308
 - Nonglial tumors 194
 - Non-Hodgkin's lymphoma, for staging FDG PET-CT evaluation 15
 - Noninfectious vasculitides 285
 - Non-invasive 3.0 T MR lymphangiography 769
 - Non-Krukenberg metastatic tumors 416
 - Nonmolecular breast imaging modalities 353
 - Nonmucinous neoplasms 427–428, 431–432
 - Nonobstructive hydronephrosis 524
 - Nonradioactive iodine 144
 - Non-small-cell lung cancer (NSCLC) 335, 340
 - Nonsteroidal anti-inflammatory drugs 328
 - Nontumoral thrombosis 295
 - Normal/near-normal V/Q scans 311
 - Normal pressure hydrocephalus (NPH) 176
 - Novel PET agents 369–370
 - NPC. *See* Nasopharyngeal carcinoma (NPC)
 - NPH. *See* Normal pressure hydrocephalus (NPH)
 - NPV. *See* Negative predictive value (NPV)
 - NSCLC. *See* Non-small-cell lung cancer (NSCLC)
 - N staging in lung cancer 336–339
 - Nuclear cardiology
 - guide therapy 264
 - and IHD
 - diagnosis 261–262
 - management 257
 - prognosis 262–266
 - special patient populations 266
 - Nuclear magnetic resonance (NMR) 40
 - Nuclear medicine
 - correlative assessment across 212
 - for COVID-19 infection 328
 - ⁶⁸Ga PET/CT imaging in 320–324
 - imaging 33, 133, 198–199
 - amino acid tracers. *See* Amino acid tracers
 - ¹⁸F-fluorodeoxyglucose 199
 - PET 35–37
 - SPECT 33–35
 - incidental breast findings in 371–373
 - imaging male patients 371
 - male patients 371
 - Na¹⁸F bone imaging 371
 - pediatric patients 373
 - ⁸²Rb cardiac imaging 371
 - metastable nuclide for 145
 - physicians, and CT 4
 - in pulmonary infection and inflammation 320
- O**
- Obstructive hydronephrosis 524
 - Occipital lobes 56
 - Ocular globe 73
 - Odontoid process 118
 - OEF. *See* Oxygen extraction fraction (OEF)
 - Olfactory fossa 71
 - Olfactory nerve 60
 - Oligometastatic prostate cancer 140
 - Omental bursa 103
 - Omentum 101, 103
 - One-day protocol 258
 - OPES. *See* Oropharyngo-esophageal scintigraphy (OPES)
 - Optic nerve 60
 - Oral cavity 66
 - anterior 232
 - boundaries 67
 - posterior 234
 - structures 67
 - tumors of 231
 - Oral contrast, in CT scanning 7–10
 - Oral transit time (OTT) 386
 - Orbit
 - bone structure 71
 - boundaries 71–72
 - ocular globe 73
 - preseptal space 71–72
 - retro-ocular spaces 73
 - Ordered subsets expectation maximization (OSEM) algorithm 38
 - Oropharyngo-esophageal tract 383
 - anatomy and physiology 383–384
 - functional motility swallowing disorders 384
 - radionuclide evaluation of 385–388
 - patient preparation and scintigraphic acquisition 386
 - qualitative and quantitative image processing 386–388
 - structural abnormalities of esophagus 388–390
 - Oropharyngeal carcinoma 229
 - chemotherapy of 240
 - combined radio-chemotherapy 246
 - Oropharyngeal fascia 61
 - Oropharyngo-esophageal scintigraphy (OPES) 385, 387, 388
 - with liquid bolus 389
 - patient with dermatomyositis and dysphagia 388
 - Oropharynx 64, 219, 229
 - Orthopantomography 233

- Osseous metastases pain
 - beta-emitting therapeutic radiopharmaceuticals 849
 - discharge and follow-up 850
 - efficacy 850–851
 - functional imaging 850
 - laboratory investigations 850
 - pretreatment 850
 - safety 851
 - therapy administration 850
- Osseous metastatic disease 367, 369, 608–614
- Osteoarthritis (OA) 590, 592
- Osteoblastoma 632–633
 - CT 632–633
 - ¹⁸F-FDG PET/CT 633
 - MRI 633
 - ^{99m}Tc-MDP bone scan 633
 - plain X-ray 632
 - symptoms 632
- Osteoid osteoma, spinal 630–632
 - clinical features 630
 - CT 631, 632
 - etiology of 630
 - MRI 631, 632
 - PET 631
 - PET/CT 632
 - plain X-ray 630–631
 - scintigraphy 631
 - SPECT/CT 632
- Osteomyelitis 596–598
- Osteoporosis 599, 600, 659–669
 - clinical diagnosis of 659
 - fracture risk assessment 659
 - imaging
 - CT 662, 664
 - dual-energy absorptiometry 659–664
 - MRI 666–669
 - PET 665–666
 - quantitative computerized tomography 664–665
 - quantitative ultrasound 668
 - radiography 660, 661
 - pathophysiology 659
 - in United States 659
 - in women 659
- Ostiomeatal complex 71
- OTT. *See* Oral transit time (OTT)
- Ovarian cancer 563–571
 - CT scan 565
 - FDG PET/CT 566–568
 - future directions for 570, 571
 - MRI 565–566
 - PET/MRI 567, 569
 - post-therapy assessment 569–570
 - CA-125 levels 569
 - CT scan 569
 - FDG PET/CT 569–571
 - MRI 569
 - pre-operative assessment 564
 - screening for 564
 - transvaginal sonography 564–565
- Ovaries 5, 110–111
- Oxygen extraction fraction (OEF) 165–166
- p**
 - PA. *See* Aspiration percentage (PA)
 - Paget disease 599, 602
 - PAN. *See* Polyarteritis nodosa (PAN)
 - Pancreas 93–95
 - parts 93
 - vascularization of 93–95
 - Papillary thyroid cancer (PTC) 237, 698
 - Paracardiac mediastinum 84–85
 - Parahippocampal gyrus 164
 - Parallax error 37
 - Paranasal sinuses 70
 - anatomical landmarks in CT 71
 - consist of 71
 - malignant disease of 224–225
 - SCC of 225
 - Parapharyngeal space 64, 65
 - Paraspinal muscles 119
 - Parathyroid
 - anatomy 492
 - embryology 492
 - imaging 492–495
 - 4D-CT 492, 493
 - MRI 493
 - ^{99m}Tc-sestamibi scintigraphy 493
 - overview of 492
 - PET and PET/CT 493
 - SPECT-CT 493–495
 - ultrasound 492
 - Parenchymal peak-time activity ($T_{\max}$) 523
 - Parietal lobes 55–56, 57
 - Parietal peritoneum 101
 - Parietotemporal cortex, in Alzheimer disease 172–173
 - Parkinson's disease (PD) 141
 - DAT-SPECT 184–185
 - diagnosis of 183, 184
 - neuromelanin-sensitive MRI 184
 - other parkinsonisms 185
 - and secondary parkinsonian conditions 184
 - Parotid malignancy, SCC 227
 - Parotid space 66
 - Parotitis, post RT edema and 243
 - Partial response (PR) 195
 - Partial volume correction (PVC)
 - methods 22, 37
 - Partial volume effects (PVEs) 34, 37
 - PCC. *See* Posterior cingulate cortex (PCC)
 - PCP. *See* Pneumocystis carinii pneumonia (PCP)
 - PD. *See* Parkinson's disease (PD); Progressive disease (PD)
 - PE. *See* Pulmonary embolism (PE)
 - Peak systolic velocity (PSV) 526, 527
 - Pediatric disease
 - bone scintigraphy
 - chronic nonbacterial osteomyelitis 696
 - Legg–Calvé–Perthes disease (LCPD) 696–697
 - ^{99m}Tc-labeled disphosphonates 696
 - neuroblastoma 697–698
 - brain flow imaging
 - in brain death 709
 - cisternography 709
 - ommaya reservoir 709
 - planar radionuclide angiogram 708
 - gastrointestinal scintigraphy
 - gastroesophageal (GE) reflux 709–710
 - gastroparesis 710–711
 - Meckel's diverticulum 711
 - hepatobiliary scintigraphy 712–713
 - lung perfusion imaging
 - bronchopulmonary sequestration 705
 - cardiac shunts 704
 - congenital heart disease 704
 - ^{99m}Tc-macroaggregated albumin (MAA) 703
 - neonatal patients 704
 - postsurgical evaluation 705–706
 - pulmonary embolism 706
 - vascular abnormalities 704
 - neuroimaging
 - ¹⁸F-sodium fluoride PET 694–695
 - PET-CT 693–694
 - PET-MRI 693
 - nuclear voiding cystogram 708
 - PET-CT imaging 693
 - renal imaging
 - diuretic renography 706–707
 - radiopharmaceutical agents 706
 - renal cortical scintigraphy 707–708
 - SPECT myocardial perfusion imaging
 - coronary artery anomalies 702–703
 - kawasaki disease 703
 - ^{99m}Tc-tetrofosmin agents 700
 - thyroid scintigraphy
 - pathophysiology 698
 - pediatric thyroid nodules 698
 - thyroiditis 700
 - thyroid malignancy 698, 700
- Pediatric-oncologic patients 371–373
- Pediatric patients, gynecomastia in 373
- Pelvic girdle 123–126
- Pelvis, anatomy of 109–116
 - false pelvis 109
 - female 109–114
 - male 114–115
 - peritoneal and extraperitoneal spaces 115–116
 - true pelvis 109

- Peptide receptor radionuclide therapy (PRRT) 838
- adverse effects 842
 - amino acid formulation 841
 - checklist 839
 - goals of 839
 - laboratory investigations 841
 - ¹⁷⁷Lu-DOTATATE-based 841
- Perfusion defect 311
- Perfusion imaging 196
- DCE-MRI 197
 - DSC-MRI 196–197
- Perfusion scintigraphy, ventilation
- scintigraphy and 324–325, 327–328
- Perfusion-weighted image (PWI) 166, 167
- Perineural tumor, extension 227, 229
- Peripheral zone (PZ), prostate gland 533
- Periprosthetic infection 596–599
- bone scintigraphy 598
 - ¹⁸F-FDG PET 597–599
 - ¹⁸F-NaF PET 599
 - MRI 597
 - SPECT/CT 598
- Perirenal space 106, 108
- Peritoneal dissemination, of gastric cancer 414, 417
- Peritoneal ligaments 102
- Peritoneal mucinous carcinomatosis 430
- Peritoneum 101
- Peritumoral radiotracer injection 361, 362
- Perivertebral space (PVS) 67, 119
- PET. *See* Positron emission tomography (PET)
- of spinal cord 647
 - spinal osteoid osteoma 631
- PET/CT 47
- artifacts in fusion 12–15
 - attenuation correction artifacts 12
 - beam hardening artifact 12, 14
 - motion artifacts 12
 - radiopharmaceutical related 15
 - truncation artifacts 14–15
 - basics 2
 - bone and soft-tissue tumor
 - biopsy 606–607
 - restaging and detection of recurrence 607, 608
 - bone and soft-tissue tumors 605
 - carcinoma of left breast 12
 - ¹¹C-choline 139
 - CT protocols in 11
 - dental metal artifacts in 221
 - display of fused images 11
 - ¹⁸F-choline 139, 140
 - FDG 2, 136–138
 - clinical examples 16–17
 - clinical indications of whole-body 136
 - colon cancer examined by 139
 - non-Hodgkin's lymphoma for 15
 - normal biodistribution 3
 - physiological causes and sites 3, 4, 5–6
 - preparation for 3
 - principle 2–3
 - scan acquisition 3
 - and SUV 3–4
 - tracers beyond 16–17
 - ¹⁸F-flutemetamol 143
 - with ¹⁸F-NaF 134–136
 - with ⁶⁸Ga-DOTATOC 142
 - MIP image of 7, 8, 10, 13
 - multiple myeloma 640–641
 - pelvic region 9
 - prototype of scanner 11
 - PSMA 540–545
 - radiolabeled choline 139–140
 - spinal lymphoma 636, 637
 - spinal osteoid osteoma 631
 - spine metastases 644, 645
 - traumatic fractures 582
- PET MPI 259, 261, 262
- PET/MR 47–48
- PET/MRI imaging systems 138, 369–370
- advantages 208
 - bone and soft-tissue tumors 608
 - development of 134
 - diabetic foot infection 594
 - for endometrial cancer 561–562
 - IDH polymorphism prediction 209
 - multiple myeloma 641
 - in neuro-oncology 207–212
 - ovarian cancer 567, 569
 - of spinal cord 647
 - spine metastases 644
- PETVAS score 289
- Peutz-Jeghers syndrome 441
- PFS. *See* Progression-free survival (PFS)
- Pharmacological stress test 258–260
- characteristics of vasodilator in 258
 - contraindications and indications for early termination 259
 - dobutamine 258
 - types 258
- Pharyngeal-basilar fascia 62, 63
- Pharyngeal mucosal space 62–64
- nasopharynx 62–64
 - oropharynx 64
- Pharyngeal transit time (PTT) 386
- Pharynx 220
- Pheochromocytomas 500–503
- Photomultiplier tubes (PMTs) 21, 23, 33–34, 47
- Photo-peak energy window 22
- Phrenicocolic ligament 101
- Physical principle on CT technique 31–32
- Piezoelectricity 44
- PIOPED. *See* Pulmonary embolism diagnosis (PIOPED)
- Piriform recess, squamous cell carcinoma of 236
- Pitch 31, 32
- Pituitary gland 494–497
- anatomy of 494–496
 - imaging
 - CT 496
 - ¹⁸F-FDG PET/CT 496, 497
 - MRI 496
 - pituitary adenomas 496, 497
 - Rathke's cleft cysts 497
- Plain radiography
- bone and soft-tissue tumors 601
 - diabetic foot infection 593
- Plain X-rays, spinal
- infection 626
 - osteoid osteoma 630–631
 - osteosarcoma 637
 - trauma 647–648
- Planar ^{99m}Tc-MAA imaging
- “hot quadrate” sign on 476, 479
 - liver mapping process 480
- Planar V/Q images 311–312, 315
- perfusion defects of lung 313, 317, 318
 - pleural effusions 314
 - radiation exposure 321
- Platelet derived growth factor alpha (PDGFRa) 419
- Pleural diseases 343–344
- Pleural surfaces 85–86
- PMB. *See* Post-menopausal bleeding (PMB)
- PMP. *See* Pseudomyxoma peritonei (PMP)
- PMR. *See* Polymyalgia rheumatica (PMR)
- PMTs. *See* Photomultiplier tubes (PMTs)
- Pneumocystis carinii pneumonia (PCP) 320
- Pneumonia 325–326
- Pneumonitis 320
- PNFA. *See* Progressive nonfluent aphasia (PNFA)
- Polyarteritis nodosa (PAN) 291
- Polymicrogyria 180
- Polymyalgia rheumatica (PMR) 290
- Portal vein, anatomical variants of 91
- Positron–electron annihilation reaction 35
- Positron emission tomography (PET) 1, 2, 35–37, 133, 163, 219, 838
- and axillary lymph node evaluation 366
 - block detector arrangement. 36
 - in breast cancer 362–363, 370, 371
 - distant metastases 366–369
 - initial staging 365–366
 - primary 363–365
 - data acquisition 35–36
 - developments 38–39
 - FDOPA 202
 - FET 201–202, 206, 207
 - FLT 203
 - FMISO 203–204
 - image reconstruction 38

- Positron emission tomography (PET) (*cont'd*)
- MET 200
 - NETs 513
 - and non-PET radionuclides 285
 - novel agents 369–370
 - osteoporosis 665–666
 - physical principles of 35
 - quantitative data corrections in 37–38
 - radiopharmaceuticals 134–144
 - radiotracers, characteristics of 260
 - suspected disease recurrence and restaging 369
 - transaxial 38
- Positron emission tomography-computed tomography. *See* PET/CT
- Positron emission tomography/magnetic resonance imaging (PET/MRI)
- brain dementia
 - frontotemporal dementia (FTD) 800
 - functional neuroimaging 800
 - morphological features 801
 - brain tumors
 - advanced modalities 789
 - advantages 789
 - central nervous system (CNS) 788
 - computed tomography 788
 - ¹⁸F-fluoromisonidazole (FMISO) 789
 - limitations 788
 - radiotracers 789
 - volumetric interpolated breath-hold examination (VIBE) 789
 - cardiac sarcoidosis 804, 806–808
 - head and neck cancer
 - challenges of 790
 - characterization 789
 - disadvantages 790
 - lymph node involvement 790
 - prognostication 789
 - hepatocellular carcinoma 791
 - multiple myeloma 796, 798
 - pancreas disease
 - ¹⁸F-FDG PET/CT 792–794
 - intraductal papillary mucinous neoplasms (IPMNs) 792
 - pancreatic neuroendocrine tumors (PNETs) 795
 - pediatric lymphoma
 - Ann Arbor classification 800
 - non-Hodgkin lymphomas (NHLs) 798
 - prostate cancer
 - diagnostic value 795
 - prostate-specific antigen (PSA) 795
 - restaging settings 795
 - rectal cancer 796, 797
 - retroperitoneal fibrosis (RPF)
 - baseline 802
 - evaluation of 802–803
 - imaging 802
 - medical treatment 802
 - post-therapy 803
 - vasculitis 804, 807
 - Posterior aortic arch 81
 - Posterior cervical space 67
 - Posterior cingulate cortex (PCC) 164, 165, 172
 - Posterior cingulate gyrus 172
 - Posterior fossa 61
 - Posterior inferior parietal lobe 164
 - Posterior oral cavity 234
 - Posterior pararenal space 106, 108
 - Posterior segment bronchi 76
 - Posterior thoraco-lumbar fascia (PTLF) 122
 - Post-menopausal bleeding (PMB) 555
 - Postoperative cerebral hyperperfusion syndrome (CHS) 169–170
 - Post-reconstruction approach 37
 - Post-styloid parapharyngeal space 64
 - Post-therapeutic findings, in head and neck diseases 239–245
 - Power Doppler 46
 - PR. *See* Partial response (PR)
 - Precuneus 172
 - Pregnancy, pulmonary embolism and 680–681
 - Presacral fascia 113
 - Preseptal space 71–72
 - Pre-styloid parapharyngeal space 64
 - Pre-therapeutic findings, in head and neck diseases 224
 - Prevertebral layer/fascia 61
 - Pre-vertebral space. *See* Perivertebral space
 - Prevesical space 116
 - PRF. *See* Pulse repetition frequency (PRF)
 - Primary breast cancer 363–365
 - Primary hepatic malignancy 467–470
 - Primary motor cortex 56
 - Primary spinal tumors 628, 629
 - Probe operation 45
 - Prognostic staging, for breast cancer 365
 - Progression-free survival (PFS) 196
 - Progressive disease (PD) 195
 - Progressive nonfluent aphasia (PNFA) 175, 176
 - Progressive supranuclear palsy (PSP) 188–189
 - Propagation speed, of sound waves 42–43
 - ProstaScint 540
 - Prostate cancer (PC) 371, 373, 466, 534
 - bone-specific imaging in 547–548
 - ¹⁸F-sodium fluoride 547–548
 - ^{99m}Tc-phosphonates 547
 - castrate-resistant PC (CRPC) 843
 - discharge and follow-up 844
 - efficacy 845
 - functional imaging 843
 - indications of 844
 - laboratory investigations 844
 - ¹⁷⁷Lu-PSMA RLT 843
 - PET/MRI 549–550
 - safety 845
 - theranostics 549
 - therapy administration 844
 - Prostate diseases 534
 - Prostate embryology and anatomy 533–534
 - Prostate gland, zonal anatomy 533
 - Prostate imaging 534–550
 - future prospects 550
 - molecular 537–545
 - ¹¹C-acetate PET/CT 538–539
 - ¹¹C-choline PET/CT 537, 538
 - FDG PET/CT 537, 538
 - ¹⁸F-FACBC PET/CT 539–541
 - other radiotracers 545–546
 - non-molecular 534–537
 - CT scan 535
 - MRI-guided biopsy 536–537
 - multiparametric prostate MRI 535–536
 - transrectal ultrasound 534–535
 - ultrasound 534–535
 - prostate cancer 534
 - bone-specific imaging in 547–548
 - ¹⁸F-sodium fluoride 547–548
 - hybrid PET/MRI 549
 - ^{99m}Tc-phosphonates 547
 - theranostics 549
 - Prostate-specific membrane antigen (PSMA) 204, 411, 644, 843
 - ligands 540
 - miTNM staging 543, 545, 546
 - PET/CT 540–545
 - PSMA-RADS score 545, 546
 - receptors 530
 - theranostics 549
 - Prostate vesicles 114–115
 - Prostatitis 534
 - Prosthetic graft material 302, 303
 - Pseudo-diffusion coefficient 198
 - Pseudomyxoma peritonei (PMP) 427, 430–431
 - PSMA. *See* Prostate-specific membrane antigen (PSMA)
 - PSMA PET/CT 531
 - PSP. *See* Progressive supranuclear palsy (PSP)
 - PSP-Richardson syndrome (PSP-RS) 188
 - Pterygopalatine fossa 72
 - PTLF. *See* Posterior thoraco-lumbar fascia (PTLF)
 - PTT. *See* Pharyngeal transit time (PTT)
 - Pulmonary arteries 83–84, 679, 680
 - Pulmonary embolism (PE) 310–311, 680–681
 - chest radiograph 311

- hybrid imaging in diagnosis 312–315
 - interpretation
 - using planar V/Q images 311–312
 - using tomographic images 312
 - Pulmonary embolism diagnosis (PIOPED) 311
 - Pulmonary epithelial permeability studies 315–318
 - Pulmonary hilum, anatomy of 74
 - Pulmonary hypertension 326–327
 - Pulmonary infection and inflammation 320
 - Pulmonary infections
 - pneumonia 732
 - sarcoidosis
 - clinical presentation 734–735
 - treatment response 735
 - tuberculosis 732–734
 - common sites 733
 - diagnosis 733
 - latent tuberculosis infection 734
 - lymphatic pattern 733
 - standardized uptake value (SUV) 734
 - WBC imaging 733
 - Pulmonary scintigraphy
 - for cardiopulmonary diseases 325–327
 - in COPD 324–325
 - Pulmonary system
 - anatomy of
 - bronchopulmonary segmental 308
 - gross anatomy 308
 - blood supply 310
 - conduction zone 308–310
 - COVID-19 infection 327–328
 - lymphatic drainage 310
 - nuclear medicine 320
 - ⁶⁸Ga PET/CT imaging in 320–324
 - in infection and inflammation 320
 - pulmonary embolism. *See* Pulmonary embolism (PE)
 - pulmonary epithelial permeability studies 315–318
 - quantitative lung scintigraphy 318–319
 - respiratory zone 310
 - tracheobronchial tree 308
 - Pulmonary ventilation perfusion (V/Q) scans 680, 681
 - Pulsed wave (PW) Doppler 46
 - Pulse repetition frequency (PRF) 45
 - PWI. *See* Perfusion-weighted image (PWI)
- q**
- Quantitative data corrections 37–38
 - Quantitative lung scintigraphy 318–319
 - Quantitative method 293
 - Quantitative ultrasound (QUS)
 - osteoporosis 668
- r**
- RA. *See* Aspiration area (RA)
 - Radiation therapy 320
 - Radio frequency (RF) system 40
 - Radiography
 - HO 584
 - osteoarthritis 590
 - Radioguided surgery 159
 - of breast cancer 158
 - Radioimmunotherapy (RIT)
 - adverse effects 862
 - antibody 860
 - antigen 860
 - clinical applications 860
 - clinical studies 862
 - efficacy 861
 - functional imaging 860
 - properties of 860
 - radionuclide 860
 - safety 861
 - targeted malignancy 860
 - Radioiodine 144–145, 854
 - Radiolabeled autologous leukocytes, scintigraphy with 401–402
 - Radiolabeled choline 139–141
 - advantages 140
 - ¹¹C-choline 139
 - ¹⁸F-choline 139
 - Radiology, correlative assessment across 212
 - Radionuclide angiography (RNA) 269
 - Radionuclide bone scan scintigraphy 367
 - Radionuclide therapy
 - discharge and follow-up 856
 - efficacy 856
 - future aspects 861–862
 - goals of 855
 - hyperthyroidism 852
 - meta-Iodobenzylguanidine (mIBG) 846
 - neuroendocrine neoplasms (NEN) 840
 - osseous metastases pain 850
 - pretreatment 855
 - prostate cancer (PC) 844
 - radioimmunotherapy (RIT) 861
 - safety 856–857
 - selective internal radiation therapy (SIRT) 857
 - therapy administration 856
 - thyroid cancer 855
 - Radiopharmaceuticals 133
 - for NET 514, 515, 517
 - PET 134–144
 - amiloxyd imaging 143–144
 - ¹⁸F-DOPA 141
 - ¹⁸F-FDG 136–139
 - ¹⁸F-NaF 134–136
 - ⁶⁸Ga-DOTATOC 141–143
 - radioguided surgery 159
 - radiolabeled choline 139–141
 - small bowel and colon 393–394
 - SPECT 144–158
 - ¹²³I-Ioflupane 154–155
 - ¹²³I-metaiodobenzylguanidine 156
 - ¹³¹Iodine 144–145
 - labeled leukocyte 154, 155
 - myocardial perfusion imaging 151–154
 - radioguided surgery 159
 - renal scintigraphy 148–151
 - ^{99m}Tc-macroaggregatelbumin 156–158
 - ^{99m}Tc-MDP 133, 134, 147–148
 - ^{99m}Tc-Technetium 145–146
 - Radiotherapy 243
 - and parotitis 243
 - of retro-auricular SCC 244
 - tumor recurrence of larynx 245
 - Radiotracers 177
 - injection techniques 361–362, 363
 - myocardial perfusion imaging 258–260
 - SLN localization technique 362
 - uptake in breast 371–373
 - imaging male patients 371
 - imaging pediatric patients 373
 - Radon space 32, 33
 - Radon transform 31
 - RANO. *See* Response Assessment in Neuro-Oncology (RANO)
 - Rasmussen's encephalitis 181–182, 183
 - Rathke's cleft cysts 497
 - ⁸²Rb cardiac imaging 371
 - Real-time ultrasound, image fusion
 - of 48–49
 - RECIST. *See* Response Evaluation Criteria in Solid Tumors (RECIST)
 - Reconstruction methods
 - CT 32–33
 - PET 38
 - Rectal adenocarcinoma 434, 435, 437
 - Rectum 113–114
 - Red blood cells 304
 - Reflection 43, 44
 - Reflux esophagitis 444
 - Refraction 43
 - and artifacts 44
 - and reflection 44
 - Regional lymph node 366
 - Regional spine anatomy 117–123
 - cervical spine 117–119
 - lumbar spine 121–122
 - sacrum and coccyx 123
 - thoracic spine 119–121
 - Region of interest (ROI) 136
 - Relative renal uptake ratio 523
 - Relaxation time T1 42
 - Relaxation time T2 42
 - Remote effect 163
 - Renal arteries 105
 - Renal cell carcinoma (RCC) 528

- Renal imaging
 - diuretic renography 706–707
 - radiopharmaceutical agents 706
 - renal cortical scintigraphy 707–708
 - Renal masses 528–530
 - Renal osteodystrophy 599, 601
 - Renal parenchymal function phase 523
 - Renal perfusion phase 523
 - Renal scintigraphy 148–151, 676–679
 - acute tubular necrosis 679
 - renal transplant evaluation 527
 - urinary tract obstruction 676–679
 - urine leak 679
 - vascular compromise 679
 - Renal transplant evaluation 526–528
 - Renal vascular compromise 679
 - Renal veins 105
 - Renin-angiotensin-aldosterone system (RAAS) 525–526
 - Renovascular hypertension 524–526
 - Resolution correction 22
 - Resonance frequency 45
 - Respiratory zone 310
 - Response Assessment in Neuro-Oncology (RANO) 196
 - Response Evaluation Criteria in Solid Tumors (RECIST) 408
 - Retention index (RI) 386
 - Retro-ocular spaces 73
 - Retroperitoneum 106–108
 - central compartment 107
 - lateral compartments 106
 - posterior compartments 107–108
 - Retropharyngeal space 66–67
 - Retrosplenial cortex 164
 - Rheumatoid arthritis 585–589
 - ^{18}F -FDG PET/CT 586, 588–589
 - MRI 586
 - $^{99\text{m}}\text{Tc}$ -MDP scan 586, 587
 - radiography 585–586
 - ultrasound 586
 - RI. *See* Retention index (RI)
 - Right bronchus, anatomy of 74–78
 - intermediate bronchus 76
 - middle lobe bronchus 76
 - right lower lobe bronchi 76
 - RUL 76
 - Right colic artery 100
 - Right hepatic vein (RHV) 87, 93
 - Right hilum, vascular anatomy of 79
 - Right intrahepatic bile duct, anatomical variants of 94
 - Right lower lobe (RLL) bronchi 76
 - basal segment bronchus of 78, 79
 - Right lower quadrant (RLQ) mass 429
 - Right perihepatic space 103
 - Right portal vein (RPV) 88, 89
 - Right subhepatic space 103
 - Right subphrenic space 103
 - Right supramesocolic space 103
 - Right upper lobe (RUL) bronchus 74, 76
 - anterior and posterior segment bronchi 76
 - anterior segment bronchi 76
 - apical segment bronchus 76
 - level of 79
 - posterior segment bronchi 76
 - Right vertical plane 87
 - RNA. *See* Radionuclide angiography (RNA)
 - ROI. *See* Region of interest (ROI)
 - Rubidium-82 259
- S**
- Sacrum 123
 - SAEFs. *See* Secondary aortoenteric fistulas (SAEFs)
 - Salivary gland tumors 226
 - Sarcoidosis 320
 - SBNET. *See* Small bowel NET (SBNET)
 - SCA. *See* Spinocerebellar ataxia (SCA)
 - Scatter correction, problem of 22
 - Scattered photons 34
 - SCC. *See* Squamous cell carcinoma (SCC)
 - Schizencephaly 180
 - Scintigraphy
 - myocardial perfusion 671
 - spinal osteoid osteoma 631
 - testicular torsion 675, 676
 - Scintillation camera system 33
 - components of 34
 - Scintimammography 354
 - SCLC. *See* Small-cell lung cancer (SCLC)
 - Scleroderma 385
 - Scoring methodology 289
 - Screening mammography 356–357, 358
 - SD. *See* Semantic dementia (SD); Stable disease (SD)
 - SDH. *See* Succinate dehydrogenase (SDH)
 - Secondary aortoenteric fistulas (SAEFs) 303–304
 - Secondary normal pressure hydrocephalus (NPH) 176
 - Segmentation-based algorithm 48
 - Selective internal radiation therapy (SIRT)
 - adverse effects 859
 - discharge and follow-up 858
 - efficacy 859
 - functional imaging 857
 - indications 859
 - pretreatment 858
 - procedures and tests 859
 - properties of 857
 - safety 859
 - therapy administration 858
 - Semantic dementia (SD) 175
 - Seminal vesicles 114–115
 - Semiology of brain in neuroimaging 53–54
 - Semiquantitative method 293
 - Sentinel lymph node biopsy (SLNB) 360–361, 363
 - Sentinel lymph node mapping 362
 - Sentinel node 763
 - in breast cancer 766
 - in colorectal cancer 768
 - in head and neck cancer 766–767
 - in melanoma 764–765
 - in vulvar cancer 767–768
 - Seronegative
 - spondyloarthropathies 589–591
 - Severe acute respiratory syndrome virus-2 (SARS-CoV-2) 327
 - Shoulder girdle 126–127
 - Shunt malfunctions,
 - cerebrospinal 682–685
 - Sigmoid colon adenocarcinoma 433, 436
 - Signal formation, MRI 40–41
 - Signal processing 45
 - Signet ring cell carcinoma 412, 413
 - Silicon photomultipliers (SiPMs) 39
 - Single imaging modality 30
 - Single-photon emission computed tomography (SPECT) 1, 2, 33–35, 133, 163
 - image degrading factors 34–35
 - lung perfusion 312
 - perfusion imaging of heart 152–153
 - physical principles of 33–34
 - protocols in 258, 260
 - quantitative data corrections in 37–38
 - radiopharmaceuticals 144–158
 - radiotracers, characteristics of 260
 - $^{99\text{m}}\text{Tc}$ -HMPAO 166
 - Single-photon emission computed tomography-computed tomography (SPECT-CT) imaging. *See* SPECT-CT
 - Single-photon emission computerized tomography (SPECT)
 - hepatic hemangiomas 468
 - NETs 513
 - Single-photon gamma imaging
 - systems 354–355
 - Sinogram 31
 - Sinonasal melanoma 226
 - Sinonasal region 70–71
 - Sinus of Morgagni 64
 - SISCOM. *See* Subtraction of ictal SPECT coregistered to MRI (SISCOM)
 - Skeletal muscles, FDG uptake 6
 - SLDCF. *See* Superficial layer of the deep cervical fascia (SLDCF)
 - SLNB. *See* Sentinel lymph node biopsy (SLNB)
 - Small bowel and colon
 - anatomy and physiology 391
 - CT imaging 400–401
 - functional disorders 392–393
 - magnetic resonance imaging 399–400

- radionuclide evaluation 393–395
- structural abnormalities of 395–398, 401–404
- ultrasound imaging 398–399
- Small bowel malignancies 424–427
- Small bowel NET (SBNET) 425
- Small bowel transit scintigraphy 394
- Small-cell lung cancer (SCLC) 335, 342, 343
- Small intestine 98
 - duodenum 96–97
 - ileum 97
 - jejunum 97
- Small lymph nodes 250, 252
 - unspecific vs. metastatic 251
- Small vessel vasculitides (SVV) 285, 291–292
- Smoking 316
 - and lung cancer 335
- Smoldering myeloma, FDG PET/CT study for 294
- Snell's law 43
- Sodium ^{18}F -fluorine (Na^{18}F) 367
- Software-based hybrid imaging 313
- Software fusion techniques 20
- Solid-state detectors 39, 47
 - SPECT-CT scanners with 23
- Solitary pulmonary nodules (SPNs) 333–334
 - chest radiography 333
 - CT scan 333
 - FDG PET/CT 333–334
 - MRI 334
- Somatostatin receptor (SSTR)-based PET imaging
 - neuroendocrine tumor 462, 463
- Somatostatin receptor PET (SSTR PET) NETs 516, 518
- Somatostatin receptors (SSTRs) 142, 514, 515, 838
- Somatostatin receptor subtype 2 (SSTR2) 207
- Sonography. *See* Ultrasound imaging
- Sound waves, properties of 42
- Spatial encoding 41
- SPECT/CT 17, 47, 145
 - acquisition 21
 - advantages 19, 20
 - clinical examples 23–26
 - carcinoma of prostate 24
 - chronic kidney disease 25
 - left hip joint pain 24
 - pubic region pain, complaints of 26
 - recurrent pancreatitis 25
 - cost of 21
 - for COVID-19 328
 - diabetic foot infection 594
 - HO 585
 - osteoarthritis 590
 - periprosthetic infection 598
 - pleural effusions 314
 - protocols 21
 - reconstruction 21–23
 - with solid-state detectors 23
 - spinal osteoid osteoma 632
 - spinal trauma 648–649
 - spine metastases 643
 - system information 19–20
- SPECT myocardial perfusion imaging
 - coronary artery anomalies 702–703
 - evaluation of chest pain 263
 - kawasaki disease 703
 - $^{99\text{m}}\text{Tc}$ -tetrofosmin agents 700
 - radiotracers 258–260
- Sphenothmoidal recess 71
- Sphenoid sinus 71
- Spinal cord 644, 646–647
- Spinal cord, FDG uptake 6
- Spinal infection 625–628
 - bone scintigraphy 627
 - classification of 625
 - clinical features 626
 - CT 626–627
 - diagnosis of 626–629
 - ^{18}F -FDG PET/CT 627–628
 - frequency of 626
 - indications of 625
 - microbiology 626
 - MRI 627, 628
 - plain X-ray 626
 - SPECT/CT 627
 - transmission mode 626
- Spinal trauma 647–649
 - causes of 647
 - MDCTs 647–648
 - MRI 648
 - SPECT/CT 648–649
 - X-rays 647–648
- Spine anatomy 116–123
 - general 116–117
 - regional 117–123
 - cervical spine 117–119
 - lumbar spine 121–122
 - sacrum and coccyx 123
 - thoracic spine 119–121
- Spine disorders 625–649
 - benign lesions 630–635
 - aneurysmal bone cyst 634
 - eosinophilic granuloma 634
 - fibrous dysplasia 634–635
 - giant cell tumor 634
 - hemangioma 635, 636
 - osteoblastoma 632–633
 - osteoid osteoma 630–632
 - infections 625–628
 - bone scintigraphy 627
 - classification of 625
 - clinical features 626
 - CT 626–627
 - diagnosis of 626–629
 - ^{18}F -FDG PET/CT 627–628
 - frequency of 626
 - indications of 625
 - microbiology 626
 - MRI 627, 628
 - plain X-ray 626
 - SPECT/CT 627
 - transmission mode 626
- Spin-lattice relaxation 42
- Spinocerebellar ataxia (SCA) 185, 187
- Spin-spin relaxation 42
- Spiral mode 31
- Spleen 100–101
- Splenorenal ligament 101
- Splenorenal ligament (SRL) 414
- “Split atlas” 118
- SPNs. *See* Solitary pulmonary nodules (SPNs)
- Spondyloarthropathies 589–591
- Spondylodiscitis 596
- Squamous cell carcinoma (SCC) 224, 407
 - anal canal 438
 - of frontal sinus 241
 - laryngeal malignant 234, 235, 255
 - oropharyngeal 229
 - of paranasal sinuses 225
 - parotid malignancy 227
 - persistence of maxillary 243
 - of piriform recess 236
 - radiotherapy of retro-auricular 244
 - recurrence of 249, 299
 - tongue base 231, 232
 - tonsillar 230
 - of trigonum retromolare 234
- Stable disease (SD) 195
- Standardized uptake value (SUV) 136
 - FDG uptake 3–4, 227
- Standardized uptake value ratio (SUVr) 173, 174
- Standardized uptake values (SUVs) 220
- Staphylococcus aureus* 292
- Static magnetic field 40, 41
- Static scintigraphy 524
- Stomach 96
- Strength, defined 33
- Stress injuries 582–584
- Stress-only protocol 258

- Structural abnormalities of esophagus 388–390
- Subarachnoid hemorrhage (SAH) 53
- Subarachnoid space (SAS) 53, 61
- Subcarinal space 83–84
- Subcortical band heterotopia 180
- Subglottic larynx. *See* Subglottis
- Subglottis 68
- Subtraction of ictal SPECT coregistered to MRI (SISCOM) 177, 179
- Succinate dehydrogenase (SDH) 420
- Superficial cervical fascia 61
- Superficial layer of the deep cervical fascia (SLDCF) 119
- Superior mesenteric artery 98, 99, 100
- Superior orbital fissure 71, 72
- Superior vena cava 81, 85
- Supero-anterior nerve 60
- Support vector machines (SVMs) 826
- Supra-aortic mediastinum 80–81, 82
- Supra-aortic trunks (SAT) 53
- Supraglottic carcinoma, without infiltration of thyroid cartilage 235
- Supraglottic larynx. *See* Supraglottitis
- Supraglottitis 67–68
- Supra-hyoid neck 61, 62. *See also* Infra-hyoid neck
- buccal space 66
- carotid space 64
- compartments of 62–67
- masticator space 65–66
- oral cavity 67
- parapharyngeal space 64, 65
- parotid space 66
- perivertebral space 67
- pharyngeal mucosal space 62–64
- retropharyngeal space 66–67
- Suprahyoid spaces 219, 220
- Supramesocolic compartment 103
- Susceptibility weighted imaging (SWI) 53
- Suspected disease recurrence and restaging 369
- Suspensory ligaments 101
- SUV. *See* Standardized uptake value (SUV)
- SUVR. *See* Standardized uptake value ratio (SUVR)
- SVV. *See* Small vessel vasculitides (SVV)
- Swallowing artifacts 220, 223
- t**
- Takayasu arteritis (TAK) 287
- FDG PET 290
- lower sensitivity for 291
- Target heart rate 258
- Task-negative network 163
- ^{99m}Tc-based radiotracers 259
- ^{99m}Tc-diethylenetriamine pentaacetic acid (^{99m}Tc-DTPA) 133, 148, 315–316
- molecular structure of 151
- pulmonary capillary epithelial permeability 315–316
- renal scintigraphy with 149, 152
- ^{99m}Tc-dimercaptosuccinic acid (^{99m}Tc-DMSA) 149, 152
- ^{99m}Tc-DTPA. *See* ^{99m}Tc-diethylenetriamine pentaacetic acid (^{99m}Tc-DTPA)
- ^{99m}Tc-etyl cysteinate dimer (^{99m}Tc-ECD) 177
- brain perfusion SPECT using 164, 183
- ^{99m}Tc-hexamethylpropyleneamine oxime (^{99m}Tc-HMAPO) 166, 167, 177, 183, 401, 402
- ^{99m}Tc-macroaggregatelalbumin (^{99m}Tc-MAA) 156–158
- ^{99m}Tc-mercapto acetyl tri glycine (MAG3) 149
- ^{99m}Tc-methyl-diphosphonate (^{99m}Tc-MDP) 133, 134, 147–148
- diagnostic accuracy 148
- molecular structure of 147
- whole-body bone scan
- bilateral knee prosthesis 151
- breast cancer 150
- prostate cancer 148
- suspicion of prosthesis mobilization 149
- Tc-99m MDP scintigraphy 590
- ^{99m}Tc. *See* ^{99m}Technetium (^{99m}Tc)
- ^{99m}Tc-pertechnetate 146
- ^{99m}Tc-pyrophosphate (PYP) 272
- ^{99m}Tc-radiocolloid 158, 159
- ^{99m}Tc-sestamibi 151, 153, 154
- ^{99m}Tc-World Health Organization (WHO) Tc-sestamibi MBI-guided breast biopsy 358, 359
- ^{99m}Tc-stannous fluoride (^{99m}Tc-Sn-F) 401
- ^{99m}Tc-tetraphosmin 151
- TDLU. *See* Terminal ductal lobular unit (TDLU)
- ^{99m}Technetium (^{99m}Tc) 145–146
- Temporal lobes 55, 57
- Temporoparietal junction 164
- Teratoma 347
- Terminal ductal lobular unit (TDLU) 351, 352
- Testicular torsion 673–676
- scintigraphy 675, 676
- ultrasonography 674–675
- Thallium-201 (²⁰¹Tl) 258, 259, 264
- Theory of mind 164
- Theranostics 134, 369–370
- Thigh 124, 125
- Thoracic anatomy 73
- bronchus. *See* Bronchus
- CT 73–74
- diaphragm 86
- mediastinum. *See* Mediastinum
- MRI 74
- pleural surfaces 85–86
- pulmonary hilum 74
- thoracic wall 85–86
- Thoracic aorta, FDG uptake in 291
- Thoracic cavity 85
- Thoracic malignancies
- lung cancer. *See* Lung cancer
- mediastinal tumors 344–345
- pleural diseases 343–344
- solitary pulmonary nodules 333–334
- teratoma 347
- thymoma 345–347
- Thoracic spine 119–121
- Thoracic ultrasonography (TUS), pleural diseases 343
- Thoracic wall 85–86
- Thorax 219
- Three-phase ^{99m}Tc-MDP bone scan 593–594
- Thymic epithelial tumors 345
- Thymoma 345–347
- Thymus, FDG uptake 5, 7
- Thyroglobulin 145
- Thyroid
- anatomy 485
- function 485
- imaging 485–492
- differentiated thyroid cancer 488–492
- ¹⁸F-FDG PET/CT 487–491
- FNA biopsy 485–486
- hybrid molecular imaging 488–492
- ¹²³I or ¹³¹I scan 489–491
- ¹²⁴I-PET/US fusion imaging 489
- ^{99m}Tc-DMSA scintigraphy 486
- ^{99m}Tc-MIBI scintigraphy 486, 487
- PET/MRI 492
- SPECT/CT 489, 491, 492
- SPECT/US 486
- thyroid scintigraphy 486
- ultrasound 485
- nodules 485
- Thyroid cancer 236
- functional imaging 854–855
- papillary 237
- Thyroid cartilage, supraglottic carcinoma without infiltration of 235
- Thyroid gland 81, 144, 296
- Thyroid scintigraphy 146, 486
- pathophysiology 698
- pediatric thyroid nodules 698
- thyroiditis 700
- thyroid malignancy 698, 700
- Thyroid-stimulating hormone (TSH) 851
- TID. *See* Transient ischemic dilatation (TID)
- Time–activity curve (TAC) 201
- Time gain compensation (TGC) 45
- Time needed to reach the peak filling (TTPF) 270
- Time-of-flight (TOF) technology 36

- Time to peak (TTP) 196
- Tissue
- attenuation coefficients for 43
 - interaction of ultrasound with 43–44
- TKIs. *See* Tyrosine kinase inhibitors (TKIs)
- TOF technology. *See* Time-of-flight (TOF) technology
- Tomographic imaging
- modalities
 - multiple factors 1
 - overview of 2
 - pulmonary embolism 312
- Tomographic theory 30–31
- Tongue
- muscles 220
 - tumors of 231, 232
- Tonsillar gland 238
- Tonsils, tumors of 229
- Trachea 308
- Tracheal bronchus 76
- Tracheobronchial tree 308
- Tracking systems
- electromagnetic 48–49
 - mechanical position encoding 49
- Traditional imaging techniques 30
- Traditional scintigraphy 133
- Transducers 44–45
- components 44
 - piezoelectric principle 44
 - resonance frequency 45
- Transglottic carcinoma, with cartilage infiltration 235
- Transient ischemic dilatation (TID) 264
- Transition zone (TZ), prostate gland 533
- Transmission-based methods 48
- Transperitoneal spread, of gastric adenocarcinoma 414
- Transrectal ultrasound (TRUS) 534–535
- Transthyretin amyloidosis (ATTR) 271–272
- Transvaginal sonography (TVS)
- endometrial cancer 555
 - ovarian cancer 564–565
- Transverse magnetization decay, MRI 42
- Transverse plane 87
- Transversus thoracis muscle 85
- Traumatic fractures 579–582
- Trigeminal nerve 60
- Trigonom retromolare 234
- Triple-energy window (TEW)
- technique 37
- Triple modality scanner 48
- True pelvis 109
- Truncation artifacts, in PET-CT 14–15
- Truncation correction 48
- T staging in lung cancer 335–336
- Tuberculosis 626, 627
- Tumor-Node- Metastasis (TNM) system 409
- Tumor thrombus 295
- TUS. *See* Thoracic ultrasonography (TUS)
- Type I endometrial cancer 554–555
- Type II endometrial cancer 554
- Tyrosine kinase inhibitors (TKIs) 420, 422
- U**
- UC. *See* Ulcerative colitis (UC)
- Ulcerative colitis (UC) 396–397
- Ulcers 400
- Ulegyria 182–183, 184
- Ultrashort echo time sequences (UTE) 48
- Ultrasonography 302
- testicular torsion 674–675
- Ultrasound (US) imaging 42, 236
- acute cholecystitis 469, 690
 - adrenal hemorrhage 500
 - display modes 45
 - doppler 45–46
 - in GCA 287
 - hepatic metastases 459
 - hepatobiliary imaging, biliary atresia 457
 - HO 585
 - interaction with tissue 43–44
 - nephroureteral obstruction 523–524
 - parathyroid imaging 492
 - physical principles 42–43
 - probe operation 45
 - prostate imaging 535–536
 - seronegative spondyloarthropathies 589
 - signal processing 45
 - small bowel 398–399
 - thyroid imaging 485
 - transducers 44–45
- Uncinate processes (UPs) 118
- Unenhanced CT
- ACCs 501
 - adrenal adenomas 498
 - adrenal metastases 502
 - urinary tract obstruction 677
- United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 564
- United States Food and Drug Administration (US FDA) 839
- Upper cervical spine 117–118
- Upper esophageal sphincter (UES) 383
- Upper gastrointestinal (UGI) imaging, gastric adenocarcinoma 412–413
- Upper limbs 126–127
- Ureter 105
- Urethra 112
- Urinary bladder 105
- Urinary system 104–105
- FDG uptake 5
 - kidneys 104–105
 - ureter 105
 - urinary bladder 105
- Urinomas 527
- UTE. *See* Ultrashort echo time sequences (UTE)
- Uterus 109–110
- venous drainage of 113
- V**
- VAF. *See* Vertebral artery foramen (VAF)
- Vagina 111
- Valvular heart diseases 274
- Variceal bleeding 688
- Vascular anatomy
- of left hilum 79–80
 - of right hilum 79
- Vascular graft infections (VGIs), imaging of 302–303
- Vascularization
- of bowel 98–100
 - of liver 89
 - of pancreas 93–95
 - of pelvis 112–113
 - of stomach 96
- Vascular parkinsonism 185, 186
- Vascular system, diagnostic imaging of 285
- Vascular thrombosis, benign and malignant 295–298
- Vasculitis, imaging of 285–292
- CT 286
 - ¹⁸F-FDG PET 286
 - LVV 287–291
 - MRI/MRA 286
 - MVV and SVV 291–292
 - ultrasound 286
- Vasodilator stress test 258
- Venous drainage of uterus 113
- Venous thromboembolic disease 327
- Venous thromboembolism (VTE) 295
- Ventilation defect 311
- Ventilation scintigraphy 319
- and perfusion scintigraphy 324–325, 327–328
- Ventricular system 61
- Vertebral artery foramen (VAF) 119
- Vesicoureteral reflux (VUR) 708
- VGIs. *See* Vascular graft infections (VGIs)
- Visceral peritoneum 101
- Visceral space 67–69
- hypopharynx 68–69
 - larynx 67–68
- Viz.AI ContaCT 832
- Vocal cords
- FDG uptake 5
 - transaxial CT-only image of 7
- Volar compartment, of forearm 127
- Voxel-based morphometry (VBM) 171
- Voxel-based Specific Regional analysis system for AD (VSRAD®) 171
- Voxels 31

V/Q scans

- and chest radiographs 311, 312
- diagnostic probability 311–312
 - high probability 311
 - indeterminate probability 311, 313
 - low probability 311
 - moderate probability 311
 - normal/near-normal probability 311
- perfusion scan 314, 315
- SPECT 312

VTE. *See* Venous thromboembolism (VTE)

W

Warburg effect 2

Wavelength, of sound waves 42

WBCs. *See* White blood cells (WBCs)

Wegener's. *See* Granulomatosis with polyangiitis (GPA)

White blood cells (WBCs) 292, 401

White matter (WM) 53, 55, 58–59

WHO. *See* World Health Organization (WHO)

Whole-body computed tomography (WBCT) 640

World Health Organization (WHO) 194

classification of gastric

adenocarcinoma 412

grade II and III gliomas 195

grade IV glioma 195

X

¹³³Xe inhalation method 168

X-ray tubes 33

xSPECT technology 47

Y

⁹⁰Y-microspheres therapy 476

Z

Zenker's diverticulum 389, 390